[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sun Yat-sen University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":610},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,477,0,25,[9,48,70,107,134,162,189,223,248,269,290,307,332,350,368,394,416,438,462,480,508,527,550,568,586],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100572795",false,"NCT06737913","HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma","Hepatic Arterial Infusion or Intravenous Infusion of Adebrelimab, Combined With Bevacizumab and Hepatic Arterial Infusion of FOLFOX Chemotherapy for Advanced Hepatocellular Carcinoma: a Multicenter, Open Label, Randomized Phase II Trial","HAIBrave-001","Inclusion Criteria:\n\n1. Voluntarily participate in the study and sign the informed consent form;\n2. Aged ≥18 years (calculated as of the date of signing the informed consent form);\n3. Diagnosed with hepatocellular carcinoma (HCC) by clinical or pathological means;\n4. Barcelona Clinic Liver Cancer (BCLC) stage C, with vascular\u002Fbile duct invasion or distant metastasis (excluding cases with Vp4-type tumor thrombus);\n5. No prior systemic therapy for HCC; or progression or residual lesions following prior local therapy for HCC (including but not limited to surgery, ablation, radiotherapy, or transarterial chemoembolization \\[TACE\\]), with an interval of at least one month between the last local treatment and enrollment;\n6. ECOG Performance Status (PS) score of 0-1 and Child-Pugh grade A or grade B with a score of 7;\n7. No history of autoimmune disease;\n8. An expected survival time of ≥3 months;\n9. At least one measurable lesion (per RECIST v1.1 criteria, the longest diameter of the measurable lesion on spiral CT scan must be ≥10 mm or the short axis of enlarged lymph nodes must be ≥15 mm; lesions previously treated locally can be considered target lesions if progression is confirmed per RECIST v1.1 criteria);\n10. Sufficient hematologic, hepatic, and renal function, with laboratory tests within the following parameters performed within one week prior to enrollment:\n\n    * Neutrophil count ≥1.5×10\\^9\u002FL;\n\n      * Platelet count ≥75×10\\^9\u002FL;\n\n        * Hemoglobin ≥90 g\u002FL;\n\n          * Serum ALT and AST ≤5×upper limit of normal (ULN); ⑤ Serum creatinine ≤1.5×ULN; ⑥ International Normalized Ratio (INR) \\\u003C2.3, or prothrombin time ≤ULN+6 seconds; ⑦ Albumin ≥30 g\u002FL;\n\n            * Total bilirubin ≤3×ULN.\n11. Women of childbearing potential must have a negative serum or urine pregnancy test within seven days prior to study enrollment, must not be breastfeeding, and must agree to use contraceptive measures during the study and for six months after its conclusion; men must agree to use contraceptive measures during the study and for six months after its conclusion.\n\nExclusion Criteria:\n\n1. Patients with a severe allergy to iodine contrast agents who are unable to undergo hepatic arterial infusion chemotherapy (HAIC);\n2. Use of immunosuppressants or systemic corticosteroids for immunosuppressive purposes within one month prior to randomization;\n3. Active infections that cannot be effectively controlled;\n4. Severe gastroesophageal varices; untreated or incompletely treated gastroesophageal varices (with bleeding or high risk of bleeding);\n5. Presence of brain metastases or bone metastases requiring urgent surgical or radiotherapy intervention;\n6. Pregnant or suspected to be pregnant, or currently breastfeeding;\n7. Current use or recent use (within 10 days before the initiation of the study treatment) of aspirin (\\>325 mg\u002Fday, maximum antiplatelet dose) or dipyridamole, ticlopidine, clopidogrel, and cilostazol;\n8. Thrombotic or embolic events, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, or cerebral infarction) or pulmonary embolism, occurring within six months prior to the initiation of the study treatment;\n9. Congenital or acquired immunodeficiency;\n10. History of other malignant tumors;\n11. Any of the following conditions within 12 months prior to the initiation of the study: myocardial infarction, severe\u002Funstable angina, or congestive heart failure;\n12. Renal insufficiency requiring dialysis;\n13. History of organ transplantation;\n14. Severe acute or chronic physical or mental illnesses or laboratory abnormalities that may increase study risks or interfere with result interpretation, rendering the patient unsuitable for enrollment.","ALL","18 Years",{"count":20,"type":21},76,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to evaluate the efficacy and safety of Adabrelimab (arterial or intravenous administration) combined with hepatic artery FOLFOX infusion chemotherapy and Bevacizumab as the first-line treatment of advanced stage hepatocellular carcinoma. Patients will be randomized 1:1 etither to receive hepatic arterial infusion(HAI) Adabrelimab group or IV Adabrelimab group, and both groups will receive HAI FOLFOX chemotherapy and IV Bevacizumab.",[27],"Advanced Hepatocellular Carcinoma (HCC)",[29,30,31,32,33,34],"Hepatic arterial infusion (HAI)","hepatic arterial infusion of FOLFOX chemotherapy","advanced unresectable hepatocellular carcinoma (HCC)","Adebrelimab (ADE)","Bevacizumab (Bev.)","intravenous infusion (IV)","RECRUITING","2026-06-30",{"date":38,"type":39},"2026-07-02","ACTUAL",{"date":41,"type":39},"2025-01-03",{"date":43,"type":21},"2028-12-31",{"name":45,"class":46},"Sun Yat-sen University","OTHER",3,{"id":49,"slug":4,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100637847","NCT07609121","Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC","A Randomized Phase 2 Study of Hypofractionated Concurrent Chemoradiotherapy Combined With Tislelizumab and Surufatinib in Patients With Unresectable Stage III Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Males or females aged 18 to 75 years or older;\n* Patients must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC);\n* Unresectable Stage III disease according to AJCC 8th staging system;\n* Negative for known driver gene mutations；\n* Newly diagnosed patients or patients treated with ≤ 4 cycles of chemotherapy combined with or without immunotherapy;\n* Expected survival ≥ 12 weeks;\n* WHO Performance Status (PS) score of 0 or 1;\n* Female subjects must not be breastfeeding;\n* Women of childbearing potential (WOCBP) must agree to use contraception during the study treatment and for 5 months after the last dose of study drug (i.e., 30 days \\[one ovulation cycle\\] plus approximately five half-lives of the study drug);\n* Adequate organ and bone marrow function as defined by the following criteria:\n* Forced Expiratory Volume in 1 second (FEV1) ≥ 800 mL;\n* Absolute neutrophil count ≥ 1.5 × 10⁹\u002FL;\n* Platelets ≥ 100 × 10⁹\u002FL;\n* Hemoglobin ≥ 9.0 g\u002FdL;\n* Creatinine clearance ≥ 50 mL\u002Fmin as calculated by the Cockcroft-Gault formula (Cockcroft and Gault, 1976);\n* Serum bilirubin ≤ 1.5 × upper limit of normal (ULN);\n* AST and ALT ≤ 2.5 × ULN.\n\nExclusion Criteria:\n\n* Concurrent enrolment in another clinical study, unless it is an observational(non-interventional) clinical study;\n* Mixed small cell and non-small cell lung cancer histology;\n* Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access;\n* Active or prior documented autoimmune disease within the past 2 years;\n* Active or prior documented inflammatory bowel disease (eg. Crohn's disease, ulcerative colitis);\n* History of primary immunodeficiency;\n* History of organ transplant that requires therapeutic immunosuppression;\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent;\n* Known history of tuberculosis;\n* History of another primary malignancy within 5 years prior to starting treatment, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ and the disease under study;\n* Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control.","75 Years",{"count":56,"type":21},160,[24],"This phase II trial employs a prospective, randomized, parallel-group design to evaluate the efficacy and safety of hypofractionated radiotherapy combined with tislelizumab and surufatinib. Eligible patients are randomly assigned to one of two arms: Experimental Group A receives hypofractionated chemoradiotherapy plus concurrent tislelizumab and surufatinib, followed by consolidation therapy with tislelizumab plus surufatinib; Experimental Group B receives the same hypofractionated chemoradiotherapy plus concurrent tislelizumab alone, followed by tislelizumab consolidation.",[60],"NSCLC (Non-small Cell Lung Cancer)","2026-06-29",{"date":63,"type":39},"2026-07-01",{"date":65,"type":39},"2026-06-01",{"date":67,"type":21},"2029-05-31",{"name":45,"class":46},1,{"id":71,"slug":4,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":77,"studyType":78,"phases":4,"briefSummary":79,"conditions":80,"keywords":85,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":69},"100644656","NCT07674524","Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC","Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC: A Multi-center Prospective Study in China","Inclusion Criteria:• Inclusion Criteria (Part A and Part B)\n\nSubjects must meet all of the following inclusion criteria to be eligible for enrollment (Part A and Part B):\n\n1. Diagnosis:\n\n   1. Histologically or cytologically confirmed locally advanced \\[defined as Stage IIIB\u002FC per AJCC v7.0 and not amenable to multimodality treatment\\] or metastatic (Stage IV) ALK-positive NSCLC; ALK status must be confirmed by Ventana ALK (D5F3) Companion Diagnostic (CDx) IHC (Ventana ULTRA or XT platform), FISH, PCR, next-generation sequencing (NGS), or circulating tumor DNA (ctDNA) testing;\n   2. At least one measurable target lesion per RECIST v1.1, not previously irradiated; brain metastases are allowed;\n2. No prior systemic therapy for advanced (Stage IIIB\u002FC not amenable to multimodality treatment) or metastatic (Stage IV) disease;\n3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0, 1, or 2;\n4. Age ≥ 18 years;\n5. Hyperlipidemia during first-line lorlatinib treatment, with ULN ≤ TC \\\u003C 12.93 mmol\u002FL (Grade 1-3);\n6. Life expectancy ≥ 6 months;\n7. Negative serum pregnancy test at screening for women of childbearing potential. Non-childbearing potential must meet at least one of the following:\n\n   1. Postmenopausal status: regular menstrual cessation ≥ 12 months with no other pathological or physiological cause (serum FSH level may be used to confirm postmenopausal status, if applicable);\n   2. Hysterectomy and\u002For bilateral oophorectomy;\n   3. Medically confirmed ovarian failure; All other women (including those with tubal ligation) are considered of childbearing potential;\n8. Provide signed and dated informed consent from the patient (or legal representative), indicating full understanding of the study-related information.\n\nPart B Additional Inclusion Criteria\n\nPatients with at least one prior major ASCVD event, or baseline LDL-C ≥ 4.9 mmol\u002FL ± high-risk factors.\n\nMajor ASCVD events:\n\n1. Acute coronary syndrome (ACS) within the past 1 year;\n2. History of myocardial infarction (excluding recent ACS);\n3. History of ischemic stroke;\n4. Symptomatic peripheral artery disease (PAD), including prior revascularization or amputation.\n\nHigh-risk factors (prioritized):\n\n1. Premature coronary artery disease (male \\\u003C 55 years; female \\\u003C 65 years);\n2. Familial hypercholesterolemia;\n3. History of coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI);\n4. Diabetes mellitus;\n5. Hypertension;\n6. Chronic kidney disease (CKD) stage 3-4;\n7. Current smoker. -\n\nExclusion Criteria:\n\nExclusion Criteria (Part A and Part B)\n\n1. Mixed squamous cell carcinoma, large cell carcinoma, or small cell lung cancer\n2. Prior systemic anticancer therapy for NSCLC, including chemotherapy, biologic therapy, immunotherapy, or any investigational drug\n3. Diagnosed genetic hypercholesterolemia (e.g., familial hypercholesterolemia, Part A only) or secondary dyslipidemia with a clear etiology (e.g., hypothyroidism, uncontrolled diabetes, nephrotic syndrome)\n4. Known allergy or history of severe adverse reaction to any study drug (including lorlatinib, statins, ezetimibe, or evolocumab)\n5. Presence of other severe diseases that may affect study compliance or outcome assessment, including advanced renal failure (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or severe hepatic impairment (Child-Pugh Class C)\n6. Pregnant or lactating women, or fertile individuals (male or female) unwilling to use effective contraception during the study\n7. Currently participating in another interventional clinical study that may interfere with this study; patients expected to be unable to complete follow-up or the first tumor efficacy assessment; patients with mental or psychological disorders who cannot provide informed consent or comply with study requirements (including treatment and follow-up)\n\nPart B Additional Exclusion Criteria\n\nSubjects meeting any of the following criteria will not be included in this clinical study:\n\n1. Major surgery within 4 weeks prior to randomization; minor surgery (e.g., port placement) is permitted provided the incision is adequately healed\n2. Radiotherapy within 2 weeks prior to enrollment, including stereotactic or partial brain radiotherapy. Patients who complete whole brain radiotherapy within 4 weeks prior to randomization, or palliative radiotherapy outside the CNS within 48 hours prior to randomization, are also excluded\n3. Gastrointestinal abnormalities including: inability to take oral medication; need for parenteral nutrition; prior surgery affecting absorption (e.g., total gastrectomy, gastric banding); active inflammatory bowel disease, chronic diarrhea, symptomatic diverticular disease; treatment for active peptic ulcer within the past 6 months; malabsorption syndrome\n4. Known or suspected severe hypersensitivity to the study drug or any of its excipients\n5. History of extensive, disseminated, or bilateral disease, or current Grade 3-4 interstitial fibrosis\u002Finterstitial lung disease, including but not limited to: pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, bronchiolitis obliterans, and pulmonary fibrosis\n6. Active malignancy within 3 years prior to randomization (excluding NSCLC, non-melanoma skin cancer, localized prostate cancer not requiring immediate treatment, or any carcinoma in situ)\n7. Concurrent use within 12 days prior to first lorlatinib dose of:\n\n   1. Strong CYP3A inhibitors (e.g., grapefruit juice or grapefruit\u002Frelated citrus fruits \\[Seville oranges, pomelos\\]; boceprevir, cobicistat, conivaptan, itraconazole, ketoconazole, posaconazole; ritonavir alone or with danoprevir, elvitegravir, indinavir, lopinavir, paritaprevir, ombitasvir, dasabuvir, saquinavir, tipranavir; telaprevir, troleandomycin, voriconazole. Topical use such as 2% ketoconazole cream is permitted where applicable)\n   2. Known narrow therapeutic index CYP3A substrates (e.g., astemizole, terfenadine, cisapride, pimozide, quinidine, tacrolimus, cyclosporine, sirolimus, alfentanil, fentanyl \\[including transdermal patch\\], or ergot alkaloids \\[ergotamine, dihydroergotamine\\]) (withdrawn from U.S. market)\n   3. Known strong CYP3A inducers (e.g., carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's Wort)\n   4. Known narrow therapeutic index P-gp substrates (e.g., digoxin)\n8. Other severe acute or chronic medical or psychiatric conditions, including suicidal ideation or behavior within the past 1 year, that may increase the risk of study participation or study drug use, or laboratory abnormalities that may interfere with interpretation of study results, and patients deemed by the investigator to be unsuitable for enrollment\n9. Participation in another investigational drug study within 2 weeks prior to enrollment and\u002For during the study period",{"count":56,"type":21},"24 Years","OBSERVATIONAL","For Patients and Families\n\nBrief Title: Management of 1L Lorlatinib with Hyperlipidemia in ALK+ Advanced NSCLC\n\nWhat is this study about?\n\nThis study is for people with ALK-positive non-small cell lung cancer (NSCLC) who are taking lorlatinib (Lorbrena®) as their first treatment and have developed high cholesterol (hyperlipidemia) as a side effect.\n\nWhy is this study needed?\n\nLorlatinib is a highly effective targeted therapy, but it frequently causes elevated cholesterol and triglycerides. There is currently no standard guideline on how to best manage this side effect. This study aims to find the best approach to control lipid levels while on lorlatinib treatment.\n\nWhat will happen in this study?\n\nThe study has two parts:\n\n* Part A (Observational) : About 100 participants. Doctors manage hyperlipidemia according to routine clinical practice. Researchers simply observe and record which lipid-lowering treatments are used and how well they work.\n* Part B (Randomized Controlled Trial) : 60 participants with high-risk factors are randomly assigned to either:\n* Intensive treatment: rosuvastatin + ezetimibe + evolocumab\n* Standard treatment: rosuvastatin + ezetimibe\n\nWhat tests are involved?\n\n* Blood tests for lipid levels at baseline, Weeks 4, 8, 20, and 24\n* Routine CT or MRI scans for tumor assessment\n* Some participants in Part B may have a non-invasive vascular ultrasound (FMD) test\n* Total participation per patient: up to 7 months\n\nIs this study safe?\n\n* ✅ Approved by the Ethics Committee of Sun Yat-sen University Cancer Center\n* ✅ All drugs used (lorlatinib, statins, ezetimibe, evolocumab) are already approved and widely used\n* ✅ An independent Data Monitoring Committee (DMC) monitors safety throughout the study\n* ✅ Participants may withdraw at any time without affecting their regular care\n\nFor Healthcare Providers\n\nStudy Title: Management strategy of 1L Lorlatinib with Hyperlipidemia in Stage IIIB-IV ALK positive NSCLC: A multi-center prospective study in China\n\nSponsor \u002F Investigators: Sun Yat-sen University Cancer Center (PI: Prof. Zhang Li)\n\nStudy Type:\n\n* Part A: Observational, prospective, real-world cohort study\n* Part B: Prospective, randomized controlled trial (RCT)\n\nEstimated Enrollment: 160 participants (Part A: \\~100, Part B: 60)\n\nStudy Duration: Approximately 4 years (anticipated completion: December 2029)\n\nKey Inclusion Criteria:\n\n* Stage IIIB-IV ALK+ NSCLC (confirmed by IHC, FISH, PCR, NGS, or ctDNA)\n* No prior systemic therapy for advanced\u002Fmetastatic disease\n* ECOG PS 0-2\n* Age ≥ 18 years\n* Hyperlipidemia (ULN ≤ TC \\\u003C 12.93 mmol\u002FL, Grade 1-3) while on first-line lorlatinib\n* At least one measurable lesion per RECIST v1.1\n* Life expectancy ≥ 6 months\n\nPrimary Endpoints:\n\n* Part A: Describe real-world treatment patterns for hyperlipidemia management\n* Part B: Percentage change in LDL-C from baseline to Week 12\n\nOversight:\n\n* Independent Data Monitoring Committee (DMC)\n* Trial Management Committee\n* Ethics Committee of Sun Yat-sen University Cancer Center (Approval No. B2026-159-01)\n\nParticipating Centers: 8 sites across China",[81,82,83,84],"Non-Small Cell Lung Cancer (NSCLC)","Hyperlipidemia","ALK Gene Mutation","ALK-positive",[86,87,82,88,89,90,91,92,93,94,95,96,97,98],"Lorlatinib","ALK-positive NSCLC","Lipid management","Statin","Ezetimibe","Evolocumab","PCSK9 inhibitor","Real-world study","Randomized controlled trial","Prospective study","Endothelial function","FMD","Multi-center","NOT_YET_RECRUITING","2026-06-24",{"date":61,"type":39},{"date":103,"type":21},"2026-08-01",{"date":105,"type":21},"2029-12-31",{"name":45,"class":46},{"id":108,"slug":4,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":131,"leadSponsor":133,"locationsCount":69},"100634723","NCT07543393","Nudging for Anticoagulation Adherence in Atrial Fibrillation","The Effects of Nudging Intervention in Promoting Adherence to Anticoagulation Among Patients With Atrial Fibrillation: a Randomized Controlled Trail","NUDGE-AF","Inclusion Criteria:\n\n* Age ≥18 years\n\nDiagnosed with non-valvular atrial fibrillation (AF) confirmed by medical records\n\nPrescribed oral anticoagulants (e.g., warfarin, rivaroxaban, apixaban, dabigatran, edoxaban) for at least 3 months\n\nOwn a personal mobile phone capable of receiving SMS messages\n\nWilling and able to provide written informed consent\n\nExclusion Criteria:\n\n* Severe cognitive impairment or psychiatric disorder that would preclude completion of questionnaires or adherence to the intervention\n\nLife expectancy \\\u003C6 months due to comorbid conditions\n\nCurrently enrolled in another medication adherence intervention study\n\nUnable to read or understand Chinese (since validated Chinese scales are used)",{"count":115,"type":21},84,[117],"NA","The goal of this clinical trial is to learn if a nudging intervention (using text message reminders, a medication calendar, and action planning) can help people with atrial fibrillation take their blood-thinning medication (anticoagulants) as prescribed.\n\nThe main questions it aims to answer are:\n\nDoes the nudging intervention improve medication adherence compared to usual care?\n\nHow does the intervention affect patients' beliefs about their medication and the automaticity of pill-taking?\n\nIs the intervention cost-effective?\n\nResearchers will compare participants who receive the nudging intervention with those who receive usual care.\n\nParticipants will:\n\nWatch a short educational video about atrial fibrillation and stroke prevention\n\nMake a personal plan to take their medication at the same time each day (for example, after breakfast)\n\nReceive text message reminders 1 to 3 times per week, with fewer messages over time\n\nGet a medication calendar to track daily doses\n\nAnswer a few questionnaires at the start, at 8 weeks, and at 12 weeks",[120],"Atrial Fibrillation (AF)",[122,123,124,125,126],"Nudge","Medication Adherence","Anticoagulation","Atrial Fibrillation","Randomized Controlled Trial","2026-06-23",{"date":129,"type":39},"2026-06-26",{"date":36,"type":21},{"date":132,"type":21},"2027-02-20",{"name":45,"class":46},{"id":135,"slug":4,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":4},"100642402","NCT07645846","Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal Carcinoma","A Multicenter, Single-Arm, Phase II Trial of Neoadjuvant Docetaxel and Cisplatin Combined With Dual Immunotherapy for Locally Advanced Sinonasal Carcinoma (PANDA Study)","PANDA","Inclusion Criteria:\n\n* Disease Status: Newly diagnosed, pathologically confirmed locally advanced (AJCC 8th edition Stage III-IVA) sinonasal carcinoma (SNC).\n* Suitable for radical comprehensive treatment, with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.\n* 18 to 75 years old.\n* Defined by the following laboratory test results obtained within 7 days prior to enrollment: Hematology (without blood transfusion or hematopoietic growth factor therapy within 14 days prior to testing): White blood cell (WBC) count ≥ 4.0 × 10\\^9\u002FL; Absolute neutrophil count (ANC) ≥ 2.0 × 10\\^9\u002FL; Platelet (PLT) count ≥ 100 × 10\\^9\u002FL.\n* Hepatic function: Total bilirubin \\\u003C 1.5 × upper limit of normal (ULN) (patients with known Gilbert's disease and serum bilirubin level ≤ 3 × ULN are eligible); Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase \\\u003C 1.5 × ULN. For patients positive for hepatitis B surface antigen (HBsAg), HBV-DNA must be ≤ 1000 IU\u002FmL, and prophylactic antiviral therapy is required during the study.\n* Renal function: Serum creatinine \\\u003C 1.5 × ULN, or creatinine clearance ≥ 60 mL\u002Fmin as calculated by the Cockcroft-Gault formula.\n* Coagulation: Activated partial thromboplastin time (APTT) and international normalized ratio (INR) ≤ 1.5 × ULN. Patients receiving stable doses of anticoagulant therapy (e.g., low molecular weight heparin or warfarin) with an INR within the expected therapeutic range are eligible.\n* Thyroid function: Thyroid-stimulating hormone (TSH) ≤ ULN; if abnormal, T3 and T4 levels will be evaluated, and patients with normal T3 and T4 levels are eligible.\n* Contraception: Women of childbearing potential must agree to use highly effective contraceptive measures (e.g., intrauterine device, contraceptive pills, or condoms) during the treatment period and for at least 3 months after the last dose. They must have a negative serum or urine pregnancy test within 7 days prior to enrollment and must not be lactating. Male patients must agree to use highly effective contraceptive measures during the study period and for at least 3 months after the last dose.\n* Informed Consent: Voluntary participation with written informed consent signed.\n\nExclusion Criteria:\n\n* History of other malignancies within the past 5 years, except for curatively treated basal cell carcinoma of the skin, carcinoma in situ of the cervix, and papillary thyroid carcinoma.\n* Presence of residual measurable lesions or new tumor\u002Fmetastasis according to RECIST 1.1 criteria, or deemed inoperable by a head and neck surgeon.\n* History of severe hypersensitivity reactions to other monoclonal antibodies or any components of the PD-1 inhibitors.\n* Prior and Concomitant Therapies: Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody (or any other antibody targeting T-cell costimulation or checkpoint pathways).\n* Use of high-dose glucocorticoids or traditional Chinese medicine with anti-tumor properties within 4 weeks prior to the first dose of the study drug.\n* Prior vaccination with an anti-tumor vaccine, or receipt of a live vaccine within 4 weeks prior to the first dose of the study drug.\n* Receipt of any investigational drug within 4 weeks prior to the first dose of the study drug.\n* Presence of comorbidities requiring long-term immunosuppressive therapy, or requiring systemic or local administration of corticosteroids at immunosuppressive doses prior to enrollment.\n* Concurrent Trials: Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up phase of an interventional study.\n* Recent Medical Events: Major surgery or severe trauma within 4 weeks prior to the first dose of the study drug.\n* Organ Transplantation: History of organ transplantation.\n* Autoimmune Diseases: Known or suspected active autoimmune disease.\n* Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS).\n* Concurrent positive HBsAg and positive HBV DNA copy number (quantitative detection ≥ 1000 cps\u002FmL). Positive blood screening for chronic hepatitis C (HCV antibody positive). Concurrent HBV and HCV co-infection. (Note: Patients with normal liver function who have been on oral antiviral therapy for more than one week may be eligible).\n* Failure to meet relevant laboratory criteria within 7 days prior to enrollment; abnormal coagulation function (PT \\> 16s, APTT \\> 53s, TT \\> 21s, Fib \\\u003C 1.5 g\u002FL), bleeding tendency, or undergoing active thrombolytic or anticoagulant therapy.\n\nSignificantly impaired cardiac, hepatic, pulmonary, renal, or bone marrow function. History of dementia or seizures.\n\n* Severe Infections: Severe infection (CTCAE \\> Grade 2) within 4 weeks prior to the first dose of the study drug, such as severe pneumonia requiring hospitalization, bacteremia, or infectious complications; baseline chest imaging indicating active pulmonary inflammation; presence of signs and symptoms of infection within 2 weeks prior to the first dose of the study drug, or requiring oral or intravenous antibiotic therapy (excluding prophylactic use of antibiotics).\n* Pregnancy and Lactation: Pregnant or lactating women; women of childbearing potential who refuse to use effective contraceptive measures.\n* Compliance and Legal Capacity: Refusal or inability to sign the informed consent form; presence of personality or psychiatric disorders; lack of or limited civil capacity.\n* Other: Presence of any other treatment contraindications deemed inappropriate by the investigator.",{"count":142,"type":21},23,[24],"The main objective of this prospective study is to evaluate the effectiveness and safety of a novel neoadjuvant therapy for patients with locally advanced sinonasal carcinoma (SNC). The treatment consists of the standard TP chemotherapy regimen (docetaxel and cisplatin) combined with dual immunotherapy (sintilimab and ipilimumab N01) administered before surgery. Researchers aim to determine the major pathological response (MPR) rate and long-term survival outcomes, while also exploring if this combination treatment approach can help better preserve critical facial and organ functions for SNC patients.",[146],"Locally Advanced Sinonasal Carcinoma",[148,149,150,151,152,153],"Locally Advanced","Sinonasal Carcinoma","neoadjuvant therapy","dual immune checkpoint inhibitors","Docetaxel","Cisplatin","2026-06-22",{"date":156,"type":39},"2026-06-25",{"date":158,"type":21},"2026-07-31",{"date":160,"type":21},"2030-08-01",{"name":45,"class":46},{"id":163,"slug":4,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":184,"completionDateStruct":185,"leadSponsor":187,"locationsCount":188},"100641398","NCT07661771","Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma","Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma: A Non-Inferiority, Multicenter, Randomized Phase 3 Trial","CTV-MARGIN-NPC","Inclusion Criteria:\n\n1. Age: 18 Years to 65 Years.\n2. Eastern Cooperative Oncology Group performance status ≤1.\n3. Patients with newly diagnosed, histologically confirmed nasopharyngeal carcinoma (non-keratinizing subtype).\n4. Tumor staged as T1-4N0-3M0 (AJCC 9th).\n5. Patients must sign informed consent and be willing and able to comply with the requirements of visits, treatment, laboratory tests and other research requirements stipulated in the research schedule.\n6. Women of childbearing potential and male subjects with female partners of childbearing potential must agree to use reliable contraceptive measures from screening to 1 year after treatment.\n7. For subjects requiring chemotherapy, the following are additionally required:\n\n   1. normal bone marrow function (white blood cell count \\> 4 × 10\\^9\u002FL, hemoglobin \\> 90 g\u002FL, platelet count \\> 100 × 10\\^9\u002FL);\n   2. normal liver and kidney function (total bilirubin ≤ 1.5 × upper limit of normal, alanine transaminase and aspartate transaminase ≤ 2.5 × upper limit of normal, alkaline phosphatase ≤ 2.5 × upper limit of normal, creatinine clearance rate ≥ 60 mL\u002Fmin).\n\nExclusion Criteria:\n\n1. Active tuberculosis: active tuberculosis within the past 1 year should be excluded regardless of treatment; a history of active tuberculosis \\> 1 year ago is exclusionary unless prior adequate anti-tuberculosis treatment is documented.\n2. Active infection requiring systemic treatment.\n3. Previous or concurrent with other malignant tumors, except for adequately treated non-melanoma skin cancer, cervical carcinoma in situ and thyroid papillary cancer.\n4. History of radiotherapy, except for non-melanoma skin cancer located outside the target volume of radiotherapy for nasophayngeal carcinoma.\n5. Prior or concurrent treatment for local or regional disease other than that specified in the research plan.\n6. Pregnant or lactating women (a pregnancy test is required for women of childbearing potential).\n7. Contraindications to MRI examination, for example: claustrophobia, allergy to MRI contrast.\n8. History of psychiatric disorders, alcoholism or drug abuse, and other situations assessed by the investigators that may compromise the safety or compliance of patients, such as serious disease requiring timely treatment (including mental illness), severe laboratory abnormalities, or family-social risk factors.\n9. For participants requiring chemotherapy, the following must also be excluded:\n\n   1. anti-human immunodeficiency virus positive or diagnosed with acquired immune deficiency syndrome;\n   2. uncontrolled heart disease (heart failure \\[NYHA Class ≥ 2\\], unstable angina, myocardial infarction in past 1 year, supraventricular or ventricular arrhythmia requiring treatment or intervention).\n10. For participants requiring immunotherapy, the following must also be excluded:\n\n    1. hepatitis B virus surface antigen positive and Hepatitis B virus DNA \\> 1000 copies\u002FmL;\n    2. anti-hepatitis C virus positive;\n    3. active, known or suspected autoimmune disease (including but not limited to uveitis, enteritis, hepatitis, pituitary disease, nephritis, vasculitis, hyperthyroidism, hypothyroidism and asthma requiring bronchodilators, exceptions are type I diabetes mellitus, hypothyroidism not requiring hormone replacement therapy, skin disorders not requiring systemic treatment \\[such as vitiligo, psoriasis or alopecia\\]);\n    4. previous interstitial lung disease or pneumonia requiring oral or intravenous steroid therapy;\n    5. chronic treatment with systemic glucocorticoid (dose equivalent to or over 10 mg prednisone per day, subjects who use inhaled or topical corticosteroids are eligible) or any other form of immunosuppressive therapy;\n    6. allergy to macromolecular protein preparations, or any component of PD-1 monoclonal antibody;\n    7. receiving live vaccine within 30 days prior to the first dose of PD-1 monoclonal antibody.","65 Years",{"count":171,"type":21},568,[173],"PHASE3","This is a non-inferiority, multicenter, randomized phase 3 trial aimed at investigating the impact of individualized primary clinical target volume based on margin expansion on patients' prognosis and complications compared with the consensus primary clinical target volume based on margin expansion and stepwise extension pattern for patients with newly diagnosed non-metastatic nasopharyngeal carcinoma.",[176],"Non-metastatic Nasopharyngeal Carcinoma",[178,179,180,181],"Radiotherapy","Target Delineation","Primary Clinical Target Volume","Margin","2026-06-16",{"date":154,"type":39},{"date":63,"type":21},{"date":186,"type":21},"2034-06-30",{"name":45,"class":46},4,{"id":190,"slug":4,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":196,"minAge":18,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":199,"briefSummary":200,"conditions":201,"keywords":207,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":222},"100629665","NCT07477626","Radiotherapy After Prostatectomy for Node Positive Prostate Cancer","Radiotherapy and Androgen Deprivation Therapy Versus Androgen Deprivation Therapy Alone After Prostatectomy for Node Positive Prostate Cancer (RADVAN): A Multicenter, Randomized Controlled Phase Ⅲ Trial","RADVAN","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically confirmed adenocarcinoma of the prostate.\n* Radical prostatectomy with pelvic lymph node dissection and pathologically confirmed positive pelvic lymph nodes (AJCC 8th edition: external iliac, internal iliac, obturator, presacral, periprostatic, and\u002For perirectal nodes).\n* ECOG performance status 0-2.\n* Started postoperative GnRH agonist or antagonist therapy for less than 1 year if receiving postoperative androgen deprivation therapy\\*.\n* Adequate major organ function, defined as:\n\nHemoglobin ≥ 90 g\u002FL Platelet count ≥ 75 × 10⁹\u002FL Total bilirubin ≤ 3 × ULN AST or ALT ≤ 5 × ULN\n\n* Use of effective contraception during the study and for 3 months after.\n* Written informed consent provided, with willingness and ability to comply with study visits, treatments, and procedures.\n\n  * Prior postoperative ARAT use ≤ 3 months is eligible after treatment discontinuation.\n\nExclusion Criteria:\n\n* Measurable pelvic recurrence on postoperative MRI or CT (RECIST 1.1, including prostate bed and lymph nodes).\n* Radiographically confirmed distant metastasis (M1a, M1b, or M1c).\n* Neoadjuvant hormonal therapy \\> 3 months before prostatectomy.\n* Malignancy within 5 years that may interfere with study safety or efficacy assessments.\n* Castration-resistant prostate cancer (CRPC) prior to enrollment per 2025 EAU criteria\n* Prior radiotherapy overlapping irradiation fields that may compromise normal tissue.\n* Serious comorbidities affecting study treatment.\n* Psychiatric disorders preventing understanding or compliance.\n* Any condition that, in the investigator's judgment, makes participation unsuitable.","MALE",{"count":198,"type":21},372,[173],"The goal of this clinical trial is to evaluate whether the addition of pelvic radiotherapy to androgen deprivation therapy (ADT) can delay disease progression and improve survival outcomes in patients with pathologically confirmed regional lymph node-positive (pN1) prostate cancer after radical prostatectomy.\n\nThe main questions it aims to answer are:\n\n* Does ADT combined with pelvic radiotherapy improve biochemical recurrence-free survival (bRFS) compared with ADT alone in pN1 patients?\n* Does the addition of pelvic radiotherapy improve clinical progression-free survival, metastasis-free survival, overall survival, and prostate cancer-specific survival without unacceptable toxicity?\n\nResearchers will compare ADT plus pelvic radiotherapy with ADT alone to see if combined treatment improves disease control and long-term clinical outcomes.\n\nParticipants with positive lymph nodes after prostatectomy will be randomly assigned in a 2:1 ratio to receive ADT plus pelvic radiotherapy, or ADT alone. ADT will be administered for 2 years. Patients with radiologically detectable pelvic recurrence or distant metastases after radical prostatectomy will be excluded. Safety, adverse events, and health-related quality of life will be assessed during follow-up.",[202,203,204,205,206],"Prostate Cancer (Post Prostatectomy)","Radiotherapy; Image-Guided","Prostate Cancer Non-Metastatic","Androgen Deprivation Therapy","Lymph Node Positive",[208,209,210,211,212,213,214],"prostate cancer","node positive","pN1","radiotherapy","androgen deprivation therapy","hormone therapy","prostatectomy","2026-06-15",{"date":182,"type":39},{"date":218,"type":39},"2026-03-20",{"date":220,"type":21},"2038-12-31",{"name":45,"class":46},13,{"id":224,"slug":4,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":231,"conditions":232,"keywords":238,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":247},"100616775","NCT07309991","Postoperative Hypoxemia Increases the Risk of Anastomotic Leak After Radical Esophagectomy","Inclusion Criteria:\n\n* Patients diagnosed with esophageal carcinoma or benign esophageal tumors\n* Patients requiring surgical resection of the lesion with subsequent esophageal reconstruction\n* Patients must have had at least one postoperative arterial blood gas analysis\n* Patients must have routinely undergone at least one of the following for postoperative evaluation of the anastomosis: endoscopy, CT scan, or esophagram\n\nExclusion Criteria:\n\n* Patients who did not require esophageal reconstruction\n* Patients undergoing esophageal replacement with colon\n* Patients with incomplete data","80 Years",{"count":230,"type":21},2500,"This study aims to determine whether postoperative hypoxia (arterial partial pressure of oxygen (PaO₂)\\\u003C80 mmHg) is an independent risk factor for anastomotic leakage after esophagectomy. The investigators conducted a retrospective analysis of cases from their center over the past five years, stratifying patients into Low Pa0₂ Group and Normal Pa0₂ Group based on postoperative oxygen levels and comparing the incidence of anastomotic leakage between the groups. The goal is to establish whether hypoxia is a causative risk factor and whether correcting it can reduce the risk of anastomotic leakage.",[233,234,235,236,237],"Esophageal Carcinoma","Esophageal Adenocarcinoma","Esophagectomy","PaO2","Esophageal Anastomotic Leakeage",[239],"Effect of Postoperative PaO₂ on Anastomotic Leakage Following Esophagectomy","2026-06-13",{"date":182,"type":39},{"date":243,"type":39},"2021-01-01",{"date":245,"type":21},"2026-12-01",{"name":45,"class":46},6,{"id":249,"slug":4,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":69},"100642209","NCT07654465","Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma","Rituximab Maintenance Versus Observation After Rituximab and Lenalidomide (R2) Induction in Previously Untreated Marginal Zone Lymphoma: A Multicenter, Phase 2, Randomized Trial","ROMA","Inclusion Criteria:\n\n* Able to understand and voluntarily sign the informed consent form.\n* Age ≥18 years.\n* Histologically confirmed CD20-positive marginal zone lymphoma, including extranodal, splenic, or nodal subtypes.\n* Considered unsuitable for or unable to tolerate standard chemotherapy.\n* Previously untreated with systemic anti-lymphoma therapy.\n* Measurable or evaluable disease according to Lugano 2014 criteria.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n* Adequate organ function.\n\nExclusion Criteria:\n\n* History of other malignancies that may interfere with study assessment.\n* Central nervous system involvement by lymphoma.\n* Known HIV infection or active hepatitis B\u002FC infection.\n* Active or uncontrolled infection.\n* Gastrointestinal condition that may interfere with oral administration or absorption of study treatment.\n* Pregnancy or breastfeeding.",{"count":256,"type":21},144,[24],"This is a multicenter, phase 2, randomized trial to compare rituximab maintenance with observation after rituximab and lenalidomide (R2) induction therapy in patients with previously untreated marginal zone lymphoma. Patients who achieve complete response or partial response after R2 induction will be randomized to receive rituximab maintenance or observation.",[260],"Marginal Zone Lymphoma(MZL)","2026-06-12",{"date":263,"type":39},"2026-06-17",{"date":265,"type":21},"2026-07",{"date":267,"type":21},"2031-07",{"name":45,"class":46},{"id":270,"slug":4,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":275,"enrollmentInfo":276,"targetDuration":4,"studyType":22,"phases":278,"briefSummary":280,"conditions":281,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":69},"100641897","NCT07648069","Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma","A Prospective, Single-center, Double-arm, Phase I Clinical Trial of Tumor Neoantigen Vaccine SarVac Combined With Tumor-specific Lymphocyte Reinfusion in the Treatment of Patients With Advanced or Unresectable Sarcoma-based Solid Tumors Who Failed Standard Treatment.","Inclusion Criteria:\n\n1. Before any procedures related to the research program, including screening and evaluation stage, signed informed consent.\n2. Age≥18 years old, and≤70 years old ;\n3. Pathologically diagnosed as solid tumors, including bone or soft tissue sarcoma, and staging for advanced or unresectable patients ;\n4. Patients with first-line treatment failure ;\n5. No previous tumor vaccine treatment ; no previous treatment with PD-1 antibody ;\n6. According to the RECIST1.1 standard, there are measurable lesions and superficial lesions ;\n7. The following three screening indicators should be met in the test screening period:\n\n（1）The available tumor tissue samples ( paraffin sections and fresh surgical specimens ) were used for subsequent whole exome and transcriptome sequencing analysis and primary cell culture to obtain tumor neoantigen-related mutation sequence information and gene expression.\n\n( 2 ) Available peripheral blood samples; ( 3 ) Tumor new antigen prediction analysis and in vitro laboratory testing; 8. ECOG score 0-1 ( see Appendix ) and expected survival time greater than 6 months ; 9. Patients were not allowed to use anti-tumor drugs and radiotherapy within 4 weeks before vaccination; 10. Patients with brain metastasis who were stable for at least one month after treatment can be included; 11. echocardiography showed left ventricular ejection fraction ≥ 50 %; 12. The results of laboratory tests should meet at least the following indicators :\n\n1. White blood cell count ≥ 3.0 × 109 \u002F L;\n2. absolute neutrophil count ( ANC ) ≥ 1.5 × 109 \u002F L ( without GCSF support ) ;\n3. absolute lymphocyte count ( ALC ) ≥ 1.0 × 109 \u002F L;\n4. platelet ( PLT ) ≥ 75 × 109 \u002F L;\n5. hemoglobin ≥ 90g \u002F dL ( no blood transfusion in the past 7 days ) ;\n6. Prothrombin time or INR ≤ 1.5x normal upper limit time, unless receiving anticoagulant therapy;\n7. partial thromboplastin time ( APTT ) ≤ 1.5x normal upper limit time, unless receiving anticoagulant therapy;\n8. serum creatinine ≤ 1.5 × ULN ( upper limit of normal ) ; 24-hour creatinine clearance rate ≥ 60 mL \u002F min;\n9. Aspartate Aminotransferase (AST\u002FSGOT) ≤ 2 × ULN;\n10. Alanine Aminotransferase (ALT\u002FSGPT) ≤ 2 × ULN;\n11. total bilirubin ( TBIL ) ≤ 1 × ULN 13. Females with fertility were negative in pregnancy test before treatment ; consent must be given to the use of contraception or the prohibition of same-sex or opposite-sex sexual activity during treatment; 14. During the whole experiment, we can regularly go to the research institutions to carry out relevant testing, evaluation and management.\n\nExclusion Criteria:\n\n* 1\\. Before any procedures related to the research program, including screening and evaluation stage, signed informed consent.\n\n  2\\. Age≥18 years old, and≤70 years old ; 3. Pathologically diagnosed as solid tumors, including bone or soft tissue sarcoma, and staging for advanced or unresectable patients ; 4. Patients with first-line treatment failure ; 5. No previous tumor vaccine treatment ; no previous treatment with PD-1 antibody ; 6. According to the RECIST1.1 standard, there are measurable lesions and superficial lesions ; 7. The following three screening indicators should be met in the test screening period:\n\n  （1）The available tumor tissue samples ( paraffin sections and fresh surgical specimens ) were used for subsequent whole exome and transcriptome sequencing analysis and primary cell culture to obtain tumor neoantigen-related mutation sequence information and gene expression.\n\n( 2 ) Available peripheral blood samples; ( 3 ) Tumor new antigen prediction analysis and in vitro laboratory testing; 8. ECOG score 0-1 ( see Appendix ) and expected survival time greater than 6 months ; 9. Patients were not allowed to use anti-tumor drugs and radiotherapy within 4 weeks before vaccination; 10. Patients with brain metastasis who were stable for at least one month after treatment can be included; 11. echocardiography showed left ventricular ejection fraction ≥ 50 %; 12. The results of laboratory tests should meet at least the following indicators :\n\n1. White blood cell count ≥ 3.0 × 109 \u002F L;\n2. absolute neutrophil count ( ANC ) ≥ 1.5 × 109 \u002F L ( without GCSF support ) ;\n3. absolute lymphocyte count ( ALC ) ≥ 1.0 × 109 \u002F L;\n4. platelet ( PLT ) ≥ 75 × 109 \u002F L;\n5. hemoglobin ≥ 90g \u002F dL ( no blood transfusion in the past 7 days ) ;\n6. Prothrombin time or INR ≤ 1.5x normal upper limit time, unless receiving anticoagulant therapy;\n7. partial thromboplastin time ( APTT ) ≤ 1.5x normal upper limit time, unless receiving anticoagulant therapy;\n8. serum creatinine ≤ 1.5 × ULN ( upper limit of normal ) ; 24-hour creatinine clearance rate ≥ 60 mL \u002F min;\n9. Aspartate Aminotransferase (AST\u002FSGOT) ≤ 2 × ULN;\n10. Alanine Aminotransferase (ALT\u002FSGPT) ≤ 2 × ULN;\n11. total bilirubin ( TBIL ) ≤ 1 × ULN 13. Females with fertility were negative in pregnancy test before treatment ; consent must be given to the use of contraception or the prohibition of same-sex or opposite-sex sexual activity during treatment; 14. During the whole experiment, we can regularly go to the research institutions to carry out relevant testing, evaluation and management.","70 Years",{"count":277,"type":21},16,[279],"PHASE1","The primary objective of this trial is to evaluate the safety and tolerability of the tumor neoantigen vaccine (SarcVac) in combination with a PD-1 antibody, with or without tumor-specific lymphocytes, in patients with advanced bone and soft tissue sarcoma who have failed first-line treatment. The secondary objectives are to assess the preliminary efficacy of SarcVac combined with a PD-1 antibody, with or without tumor-specific lymphocytes, in these patients and to evaluate whether the vaccine's efficacy demonstrates dose dependency.",[282,283],"Soft Tissue Sarcoma (STS)","Osteosarcoma",{"date":215,"type":39},{"date":286,"type":39},"2024-09-03",{"date":288,"type":21},"2027-06-30",{"name":45,"class":46},{"id":291,"slug":4,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":169,"enrollmentInfo":295,"targetDuration":4,"studyType":22,"phases":297,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":303,"completionDateStruct":304,"leadSponsor":306,"locationsCount":69},"100642683","NCT07650214","Study on the Effects and Mechanisms of Probiotic Supplementation in Ameliorating Uric Acid Metabolism in Asymptomatic Hyperuricemic Individuals","Inclusion Criteria:\n\n* Men and women aged 18-65;\n* Residents who have lived in Guangdong for more than one year;\n* According to the \"Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia-Related Diseases (2023 Edition)\", asymptomatic HUA is defined as a fasting serum uric acid level \\>420 umol \u002FL and no history of gout symptoms such as gouty arthritis;\n* Consent to be randomly assigned to the intervention or control group;\n* Willing to consume the probiotic products provided by the study;\n\nExclusion Criteria:\n\n* Secondary HUA caused by disease or drugs;\n* Within 3 months before participating in the study, or currently taking drugs that affect uric acid metabolism, such as azathioprine, thiazide diuretics, prednisone, etc., and unwilling to stop taking them during the study;\n* Taking or currently taking medication for gout within 3 months before participating in the study and unwilling to stop taking it during the study;\n* Abnormal liver function (AST or ALT levels are more than 3 times the upper limit of normal), abnormal renal function (glomerular filtration rate less than 60mL\u002Fmin\u002F1.73m\\^2);\n* Abnormal blood test results (such as white blood cell count \\\u003C 3.5x10\\^9 \u002FL, platelet count \\\u003C 100x10\\^9 \u002FL, hemoglobin \\\u003C 90g\u002FL) or other blood system diseases;\n* Suffering from severe cardiovascular, kidney, gastrointestinal, hepatal, and malignant tumor diseases;\n* Long-term or current use of nonsteroidal anti-inflammatory drugs, antibiotics, antihistamines, or immunomodulatory drugs, and inability to stop using these drugs within 72 hours before the start of the study;\n* Currently taking anticoagulants, anabolic steroids, hydrocortisone and other hormonal drugs;\n* Use of probiotic supplements within one month prior to participating in the study, and was unwilling to discontinue taking them during the study;\n* Frequent use (more than once a day) of multivitamins, antioxidants, herbal supplements, dietary fiber-containing supplements, and other nutritional supplements (such as inulin, fish oil, soy lecithin, niacin, dietary fiber, flaxseed, phytoestrogens, sterols, etc.), or products containing prebiotics, probiotics, synbiotics, postbiotics, etc. (such as yogurt, fermented milk, beverages, or other fermented products) within 3 months prior to study participation, and unwilling to stop taking them;\n* Self-reported weight loss of more than 7 kg or 10% in the 6 months prior to enrollment;\n* Suffering from eating disorders (such as anorexia and bulimia), dysphagia, or difficulty swallowing food or medication;\n* Unable to consume the probiotic products provided by the study as required during the study period;\n* Drink more than 2 times a day, more than 14 times a week, and are unwilling to stop drinking during the study;\n* Intolerance or food allergy related to the investigational product, drug allergy, or other issues that may affect food intake;\n* Poor venous access;\n* Women who have given birth in the past year, are pregnant, or plan to become pregnant within 6 months, or are breastfeeding;\n* Participating or planning to participate in other dietary intervention studies, drug use studies, or cosmetic or pharmaceutical application studies in the next three months;\n* Participated in clinical trials in the past 3 months;\n* Any other condition that is deemed unsuitable for the trial by a physician.",{"count":296,"type":21},68,[117],"This study aims to utilize a randomized controlled trial in asymptomatic hyperuricemic individuals to clarify the effects of four probiotic strains including Lactobacillus acidophilus on serum uric acid levels, pathways of uric acid synthesis, degradation and excretion, hyperuricemia-induced oxidative stress and chronic inflammatory responses, uric acid-related metabolites, gut microbiota composition and diversity.",[300],"Asymptomatic Hyperuricemia","2026-06-11",{"date":182,"type":39},{"date":63,"type":21},{"date":305,"type":21},"2027-12-31",{"name":45,"class":46},{"id":308,"slug":4,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":314,"targetDuration":4,"studyType":22,"phases":316,"briefSummary":317,"conditions":318,"keywords":321,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":69},"100642462","NCT07651553","Transanal Total Mesorectal Excision vs Robotic Total Mesorectal Excision","A Prospective, Randomized, Parallel-Controlled, Superiority Clinical Study Comparing Transanal Total Mesorectal Excision (taTME) and Robot-Assisted Total Mesorectal Excision (RTME) in the Treatment of Low Rectal Cancer","TaLaR03","Inclusion Criteria:Newly diagnosed patients aged 18-75 years. Pathologically confirmed adenocarcinoma (tubular, papillary, mucinous, or signet-ring). Tumor ≤7 cm from anal verge (MRI or DRE). Clinical stage T1-T3, N+, M0 (AJCC 8th ed.), suitable for sphincter-preserving TME. ASA score I-III.\n\nECOG performance status 0-1. Informed consent obtained.\n\n\\- Exclusion Criteria: Synchronous\u002Fmetachronous colorectal cancers, local recurrence, or distant metastases. Bowel obstruction, perforation, bleeding requiring emergency surgery. Involvement of sphincter or adjacent organs requiring Inter-sphincter Resection (ISR). Poor preoperative anal function\u002Fincontinence. IBD or familial adenomatous polyposis (FAP).\n\nPregnancy or lactation. Severe psychiatric illness. Other malignancies within 5 years. Severe comorbidities or infections making surgery intolerable. Judged unsuitable by investigator.",{"count":315,"type":21},216,[117],"TME remains standard treatment for rectal cancer. Both Robotic TME and taTME are innovative surgical techniques with potential advantages in low rectal cancer. To date, no clinical studies have directly compared the conversion and complication rates between taTME and RTME in this population. Therefore, the investigators propose to conduct a prospective, randomized, parallel-controlled clinical trial comparing taTME with RTME for low rectal cancer, aiming to provide high-level evidence for surgical decision-making and benefit more patients.",[319,320],"Rectal Cancer Patients","Robotic Assisted Intervention",[322,323,324],"robotic TME","taTME","rectal cancer","2026-06-10",{"date":182,"type":39},{"date":328,"type":39},"2025-06-30",{"date":330,"type":21},"2029-04-28",{"name":45,"class":46},{"id":333,"slug":4,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":275,"enrollmentInfo":338,"targetDuration":4,"studyType":22,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":69},"100428470","NCT04859465","Albumin-bound Paclitaxel Combined With Liposomal Doxorubicin in the Treatment of Advanced or Unresectable Angiosarcoma","Albumin-bound Paclitaxel Combined With Liposomal Doxorubicin in the Treatment of Advanced or Unresectable Angiosarcoma--an Open, Single Arm, Multicenter Phase II Study","Inclusion Criteria:\n\n1. The patients voluntarily participated in the study and signed the informed consent; In all advanced angiogenic sarcomas confirmed by pathology, the standard treatment failed or there was no standard treatment or the standard treatment could not be tolerated. There is at least one measurable lesion according to RECIST 1.1, mainly including angiosarcoma, epithelioid hemangioendothelioma, epitheliosarcoma hemangioendothelioma, pseudomyogenic hemangioendothelioma, Kaposi sarcoma, malignant solitary fibroma \u002F hemangiopericytoma, malignant glomus tumor, etc.\n2. Patients in advanced stage with unresectable lesions or lymph node or distant metastasis by imaging evaluation;\n3. In the past three months, there was at least one target lesion that could be measured according to RECIST version 1.1 standard, and it could be accurately measured in at least one direction (the maximum diameter needs to be recorded) by MRI or CT, including conventional CT ≥ 20 mm or spiral CT ≥ 10 mm.\n4. 18-70 years old; ECOG PS score: 0-1; the expected survival time was more than 3 months;\n5. The main organ function met the following criteria within 7 days before treatment (1) Blood routine examination standard (without blood transfusion within 14 days)\n\n   * Hemoglobin (HB) ≥ 90g \u002F L; ② Absolute neutrophil count (ANC) ≥ 1.5 × 109 \u002F L;\n\n     ③ Platelet count (PLT) ≥ 80 × 109 \u002F L.\n\n     (2) Biochemical tests should meet the following standards:\n   * Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN); ② Alanine aminotransferase (ALT) and aspartate aminotransferase AST ≤ 2.5 × ULN ALT and AST ≤ 5 ×ULN in patients with liver metastasis; ③ Serum creatinine (CR) ≤ 1.5 × ULN or creatinine clearance rate (CCR) ≥ 60ml \u002F min;\n\n     (3) Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) ≥ the lower limit of normal value (50%).\n6. Women of childbearing age should agree to use contraceptive measures (such as intrauterine device, contraceptive or condom) during the study period and within 6 months after the end of the study; women with negative serum or urine pregnancy test within 7 days before the study and must be non lactation patients; men should agree to use contraceptive measures during the study period and within 6 months after the end of the study period.\n\nExclusion Criteria:\n\n1\\) Patients who have previously received abraxane treatment.\n\n2\\) There were other malignant tumors in the past 5 years or at the same time, except for the cured cervical carcinoma in situ, skin cancer without melanoma and superficial bladder tumor (TA (non invasive tumor), tis (in situ cancer) and T1 (tumor infiltrating basement membrane);\n\n3\\) Systemic anti-tumor treatment, including cytotoxic therapy, signal transduction inhibitors, immunotherapy (or mitomycin C use within 6 weeks prior to the treatment of the trial drug), is planned within 4 weeks before the group is given or during the study medication. The radiotherapy was performed within 4 weeks before the group or the limited field radiotherapy was performed within 2 weeks before the group;\n\n4\\) With pleural effusion or ascites, respiratory syndrome (≥ CTC AE class 2 dyspnea (dyspnea 2 refers to shortness of breath when a small amount of activity is used; It can affect instrumental daily life activities);\n\n5\\) No remission of toxic reactions caused by any previous treatment was higher than that of CTC AE (4.01), excluding hair loss and lymphocyte reduction;\n\n6\\) Patients with any serious and \u002F or uncontrollable diseases, including:\n\n1. The patients with poor blood pressure control (systolic pressure ≥ 150 mmHg and diastolic pressure ≥ 100 mmHg) were found;\n2. Patients with myocardial ischemia or myocardial infarction, arrhythmia (including QTc ≥ 480ms) and ≥ 2 congestive heart failure (NYHA classification);\n3. Active or uncontrollable severe infection (≥ CTC AE Level 2 infection);\n4. Cirrhosis, decompensated liver disease, active hepatitis or chronic hepatitis need to be treated with antiviral treatment;\n5. Renal failure requires hemodialysis or peritoneal dialysis;\n6. The control of diabetes mellitus was not good (FBG) was more than 10mmol\u002Fl;\n7. The routine urine suggested that the urine protein was ≥ + +, and the 24-hour urine protein was more than 1.0 G;\n8. Patients with epilepsy and need treatment;\n\n7\\) The patients were treated with major surgery, incision biopsy or obvious traumatic injury within 28 days before entering the group;\n\n8\\) Patients with any signs of bleeding constitution or history, regardless of severity; In the 4 weeks before entering the group, there were unconnected wounds, ulcers or fractures in patients with bleeding or bleeding events ≥ CTCAE Level 3;\n\n9\\) The patients with arteriovenous thrombosis occurred within 6 months, such as cerebrovascular accidents (including transient ischemic attack), deep vein thrombosis and pulmonary embolism;\n\n10\\) The patients with active ulcer, perforation and obstruction of intestine;\n\n11\\) The patients had clinical symptoms of central nervous system metastasis (such as brain edema, hormone intervention, or brain metastasis progress); Patients who have received brain or meningeal metastasis treatment before, such as clinical stability (MRI) have been maintained for at least 2 months, and patients who have stopped systemic hormone therapy (dose \\> 10mg \u002F day prednisone or other therapeutic hormone) for more than 2 weeks can be included;\n\n12\\) The subjects were using immunosuppressant, or systemic or absorbable local hormone therapy to achieve immunosuppressive purposes (dose \\> 10mg \u002F day prednisone or other therapeutic hormone), and were still in use within 2 weeks before entering the group;\n\n13\\) The subjects had any active autoimmune disease or had a history of autoimmune disease (such as, but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism; If the subjects had vitiligo or had been completely relieved in childhood asthma, no intervention was needed in adult; Asthma in which the subjects needed bronchodilators to intervene in medicine could not be included;\n\n14\\) Subjects had active tuberculosis and immunodeficiency history including human immunodeficiency virus (HIV) or other acquired or congenital immunodeficiency disease or active hepatitis (transaminase does not conform to inclusion, hepatitis B virus (HBV) DNA ≥ 104\u002F ml or hepatitis C virus seropositive (HCV) RNA ≥ 103\u002Fml or higher); Chronic hepatitis B virus carriers with HBV DNA \\\u003C 2000 iu\u002Fml (\\\u003C 104 \u002F ml) must be treated with antiviral therapy throughout the study.\n\n15\\) According to the researchers' judgment, the subjects are not suitable for entering the group or other factors may lead to the termination in the middle of the course. For example, other serious diseases (including mental diseases) need to be treated together, there are serious laboratory abnormalities, and family or social factors, which will affect the safety of the subjects, or the collection of test data and samples;\n\n16\\) The clinical trials of other anti-tumor drugs were conducted 28 days before entering the group.",{"count":339,"type":21},69,[24],"The purpose is to explore the efficacy and safety of the combination of albumin-bound paclitaxel and liposomal doxorubicin in the treatment of advanced or unresectable angiosarcoma.",[343],"Angiosarcoma Metastatic",{"date":261,"type":39},{"date":346,"type":39},"2021-05-21",{"date":348,"type":21},"2027-11-20",{"name":45,"class":46},{"id":351,"slug":4,"hasResults":11,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":11,"sex":17,"minAge":356,"maxAge":275,"enrollmentInfo":357,"targetDuration":4,"studyType":22,"phases":359,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":363,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":367,"locationsCount":69},"100407770","NCT04589741","Toripalimab Combined With CAV\u002FIE Regimen","A Multicenter, Randomized, Parallel-controlled Phase II Study of Toripalimab Combined With CAV\u002FIE Regimen Versus Chemotherapy Alone in Patients With Advanced or Unresectable Bone and Soft Tissue Sarcoma Who Have Failed Standard Treatment","Inclusion Criteria:\n\n1. Patients voluntarily participated in the study and signed informed consent;\n\n   For all advanced or non resectable bone and soft tissue sarcomas confirmed by pathology, the standard treatment failed or there was no standard treatment. They were mainly synovial sarcoma, leiomyosarcoma, undifferentiated pleomorphic sarcoma, liposarcoma, fibrosarcoma, clear cell sarcoma, angiosarcoma, epithelioid sarcoma, malignant peripheral nerve sheath tumor, undiffertiated sarcoma, bone sarcoma, chondrosarcoma, Ewing's sarcoma, rhabdomyosarcoma, dermatofibrosarcoma protuberans, myofibroblastic sarcoma, malignant solitary fibroma, postradiation sarcoma,etc. But the pathological subtypes without standard treatment can be treated as first-line treatment, including but not limited to radiation-induced sarcoma, dedifferentiated \u002F pleomorphic liposarcoma, clear cell sarcoma, etc., except for the following types: well differentiated liposarcoma, malignant mesothelioma, gastrointestinal stromal tumor, etc;\n2. Advanced patients with unresectable lesions or lymph nodes or distant metastasis assessed by imaging;\n3. In the past three months, there was at least one measurable target lesion according to RECIST version 1.1 standard, and it can be accurately measured by magnetic resonance imaging (MRI) or computer tomography (CT) in at least one direction (the maximum diameter needs to be recorded), with conventional CT ≥ 20 mm or spiral CT ≥ 10 mm.\n4. They were 14-70 years old; ECOG PS score: 0-1; the expected survival time was more than 3 months;\n5. Within 7 days before treatment, the main organ functions met the following criteria:\n\n(1) Blood routine examination standard (without blood transfusion within 14 days)\n\n① Hemoglobin (HB) ≥ 90g \u002F L;\n\n② The absolute value of neutrophil (ANC) ≥ 1.5 × 109 \u002F L;\n\n* Platelet (PLT) ≥ 80 × 109 \u002F L.\n\n  (2) Biochemical examination should meet the following standards:\n  * Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal value (ULN);\n\n    * Alanine aminotransferase (ALT) and aspartate aminotransferase AST ≤ 2.5uln; ALT and AST ≤ 5uln with liver metastasis\n* Serum creatinine (CR) ≤ 1.5uln or creatinine clearance rate (CCR) ≥ 60ml \u002F min;\n\n  (3) Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) ≥ the lower limit of normal value (50%).\n\n  6)Women of childbearing age should agree that contraceptive measures (such as intrauterine device, contraceptive or condom) must be used during the study period and within 6 months after the end of the study; serum or urine pregnancy test negative within 7 days before study enrollment, and must be non lactating patients; men should agree that contraceptive measures must be used during the study period and within 6 months after the end of the study period.\n\nExclusion Criteria:\n\n1\\) Patients who had previously received anti-PD-1 \u002F PD-L1 antibody therapy.\n\n2\\) Other malignancies occurred or were present within 5 years, except for cervical carcinoma in situ, non melanoma skin cancer and superficial bladder tumor \\[ta (non invasive tumor), tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)\\];\n\n3\\) Systemic anti-tumor therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy (or mitomycin C within 6 weeks prior to the trial drug treatment) was planned within 4 weeks before enrollment or during the study period. Over extended field radiotherapy was performed within 4 weeks before admission or limited field radiotherapy was performed within 2 weeks before grouping;\n\n4\\) With pleural effusion or ascites, it causes respiratory syndrome (≥ CTC AE grade 2 dyspnea \\[grade 2 dyspnea refers to shortness of breath with a small amount of activity; it affects instrumental activities of daily living\\]);\n\n5\\) Any unrelieved toxic reaction higher than CTC AE (4.01) grade 1 or above caused by previous treatment, excluding alopecia;\n\n6\\) Patients with any severe and \u002F or uncontrolled disease, including:\n\n1. Patients with poor blood pressure control (SBP ≥ 150 mmHg, DBP ≥ 100 mmHg);\n2. Patients with myocardial ischemia or myocardial infarction of grade I or above, arrhythmia (including QTc ≥ 480ms) and congestive heart failure (NYHA) grade ≥ 2;\n3. Active or uncontrolled severe infection (≥ CTC AE Level 2 infection);\n4. Chronic liver disease, decompensated liver disease or decompensated hepatitis;\n5. Renal failure needs hemodialysis or peritoneal dialysis;\n6. Poor control of diabetes mellitus (FBG \\> 10mmol \u002F L);\n7. Urine routine examination showed that urine protein was ≥ + +, and 24-hour urine protein was more than 1.0 G;\n8. Patients with epilepsy and need treatment;\n\n7\\) Major surgical treatment, open biopsy or obvious traumatic injury were performed within 28 days before admission;\n\n8\\) Patients with any physical signs or history of bleeding regardless of severity; patients with any bleeding or bleeding events ≥ CTCAE 3 within 4 weeks before enrollment had unhealed wounds, ulcers or fractures;\n\n9\\) Patients who had AVT events within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism;\n\n10\\) There were active ulcer, intestinal perforation and intestinal obstruction;\n\n11\\) Subjects with clinical symptoms of central nervous system metastasis (such as brain edema, need for hormone intervention, or brain metastasis progression); patients who have previously received treatment for brain or meningeal metastasis, such as clinical stability (MRI) for at least 2 months, and who have stopped systemic hormone therapy (dose \\> 10mg \u002F day, prednisone or other effective hormones) for more than 2 weeks can be included;\n\n12\\) The subjects were using immunosuppressive agents, or systemic or absorbable local hormone therapy to achieve the purpose of immunosuppression (dosage \\> 10mg \u002F D, prednisone or other effective hormones), and continued to use them within 2 weeks before enrollment;\n\n13\\) Subjects with any active autoimmune disease or history of autoimmune diseases (e.g., but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism; if the subject has vitiligo or asthma has been completely relieved in childhood, it is not necessary to be an adult Any intervention can be included; asthma patients who need bronchodilator for medical intervention cannot be included);\n\n14\\) The subjects had active tuberculosis;\n\n15\\) According to the judgment of the researcher, the subjects are not suitable to be enrolled or there are other factors that may lead to termination of the study, such as other serious diseases (including mental diseases) requiring combined treatment, serious laboratory examination abnormalities, and family or social factors, which will affect the safety of the subjects, or the collection of test data and samples;\n\n16\\) Patients who participated in other clinical trials of anti-tumor drugs within 28 days before enrollment.","14 Years",{"count":358,"type":21},134,[24],"The aim of this study was to investigate the efficacy and safety of CAV\u002FIE chemotherapy combined with toripalimab versus CAV\u002FIE chemotherapy alone in the treatment of patients with advanced or unresectable bone and soft tissue sarcomas who failed in standard treatment.",[362],"Soft Tissue Sarcoma",{"date":261,"type":39},{"date":365,"type":39},"2020-10-23",{"date":288,"type":21},{"name":45,"class":46},{"id":369,"slug":4,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":375,"minAge":18,"maxAge":275,"enrollmentInfo":376,"targetDuration":4,"studyType":22,"phases":378,"briefSummary":379,"conditions":380,"keywords":382,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":390,"completionDateStruct":391,"leadSponsor":393,"locationsCount":69},"100642400","NCT07646301","Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer","Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Prospective Single-Arm Phase II Trial","QUARTZ-CC","Inclusion Criteria:\n\n1. Age 18 to 70 years.\n2. Histologically or cytologically confirmed cervical cancer, FIGO stage IB3 or IIA2.\n3. Imaging findings showing pelvic lymph node short-axis diameter \\\u003C 1.5 cm and para-aortic lymph node short-axis diameter \\\u003C 1.5 cm.\n4. Pathological diagnosis of cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.\n5. No prior anti-tumor therapy.\n6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n\nExclusion Criteria:\n\n1. Presence of other concurrent malignancies.\n2. Pregnant or peripartum women.\n3. History of myocardial infarction or stroke, unstable angina, decompensated heart failure, or deep vein thrombosis.\n4. Presence of NCI-CTCAE version 5.0 grade ≥2 arrhythmia, any grade of atrial fibrillation, or clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention.\n5. Active unresolved hepatitis, defined as progressive decrease in appetite, general weakness, nausea, acid reflux, aversion to oily foods, abdominal distension, or abnormal liver function with jaundice (e.g., scleral or urinary jaundice); for hepatitis B, HBV DNA \\> 1000 IU\u002FmL.\n6. Hepatic insufficiency (aspartate aminotransferase\u002Falanine aminotransferase \\> 2.5 × upper limit of normal).\n7. Renal insufficiency (serum creatinine \\> 2 × upper limit of normal).\n8. History of chronic pulmonary disease with restrictive respiratory dysfunction.\n9. History of major organ transplantation or autoimmune disease.\n10. History of severe mental illness or cerebral dysfunction.\n11. History of substance abuse or drug addiction.\n12. Use of immunosuppressive agents or systemic corticosteroids for immunosuppressive purposes (dose \\> 10 mg prednisone or equivalent) within 2 weeks prior to enrollment, with ongoing use.\n13. Coagulation abnormality (INR \\> 2.0, PT \\> 16 seconds), bleeding tendency, or ongoing thrombolytic or anticoagulant therapy (prophylactic low-dose aspirin and low-molecular-weight heparin are permitted).\n14. Congenital or acquired immunodeficiency (e.g., HIV infection).\n15. Receipt of inactivated vaccine within 30 days prior to the first dose of study treatment.\n16. Inability or unwillingness to provide written informed consent or comply with study requirements.","FEMALE",{"count":377,"type":21},103,[24],"Purpose:\n\nTo evaluate the efficacy and safety of neoadjuvant treatment with iparomlimab and tuvonralimab (QL1706), a dual PD1and CTLA4 bispecific antibody, in combination with paclitaxel and either cisplatin or carboplatin (TP\u002FTC regimen) for patients with locally advanced cervical cancer.\n\nEligibility Criteria:\n\nWomen aged 18 to 70 years with newly diagnosed, histologically confirmed cervical cancer (squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma), FIGO stage IB3 or IIA2, with no evidence of significant lymph node involvement (pelvic and paraaortic lymph nodes \\\u003C1.5 cm in short diameter), and who have not received any prior anticancer therapy.\n\nStudy Procedures:\n\nParticipants will receive up to 4 cycles of QL1706 plus TP\u002FTC chemotherapy (once every 3 weeks) prior to surgery. After 2 cycles, clinical assessment will be performed to evaluate tumor response. If tumor shrinkage is observed, treatment may continue for 2 additional cycles, followed by imaging evaluation. Depending on the response, participants with complete or partial response may undergo less extensive surgery (cervical conization plus sentinel lymph node biopsy) rather than standard radical hysterectomy. After surgery, participants who achieve a major pathological response will receive QL1706 maintenance therapy as a single agent for up to 8 additional cycles (once every 3 weeks). For participants with insufficient tumor response, standard radical hysterectomy will be performed. Postoperative adjuvant therapy (radiation or chemotherapy) will follow standard clinical guidelines.\n\nPrimary and Secondary Objectives:\n\nThe primary endpoint is the pathological complete response (pCR) rate in the resected tissue following neoadjuvant treatment. Secondary endpoints include safety (treatment related adverse events), objective response rate (ORR), 3 years overall survival, 3 years disease free survival, and quality of life.\n\nStudy Duration:\n\nTotal participation time depends on treatment response and surgical scheduling, with an expected duration of approximately 9 to 12 months (including neoadjuvant treatment, surgery, and potential maintenance therapy).",[381,148],"Uterine Cervical Neoplasms",[383,384,385,386,387,373],"Locally advanced cervical cancer","QL1706","Neoadjuvant chemoimmunotherapy","Pathological complete response","Phase II Single-arm Prospective study","2026-06-09",{"date":261,"type":39},{"date":63,"type":21},{"date":392,"type":21},"2029-07-01",{"name":45,"class":46},{"id":395,"slug":4,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":11,"sex":17,"minAge":399,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":22,"phases":402,"briefSummary":403,"conditions":404,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":415},"100642768","NCT07644897","Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma","Inclusion Criteria:\n\n1. Aged 60 years or older;\n2. Diagnosis of malignant melanoma confirmed by pathological histology or cytology examination.\n3. According to the 8th edition of AJCC staging, patients with unresectable stage III or IV melanoma;\n4. One or more lesions evaluable by RECIST1.1 standards.\n5. The Eastern Cooperative Oncology Group (ECOG) scoring system in the United States has a score range of 0-2.\n6. Total bilirubin ≤1.5× upper limit of normal (ULN); AST and AST \\\u003C2.5× upper limit of normal (ULN).(No liver metastasis), or \\\u003C5 times the upper limit of normal (ULN) (with liver metastasis);\n7. Patients with recurrent metastasis who have not previously received immunotherapy such as PD-1, PD-L1, CTLA-4 antibodies，also allowed for the enrollment of patients who had used adjuvant\u002Fneoadjuvant therapies\n\n   * If the adjuvant or neoadjuvant treatment plan includes PD(L)-1 or CTLA-4 monoclonal antibodies, it is required that only those who progress more than 6 months after the end of the treatment plan can be included in the study group.\n   * If the adjuvant or neo-adjuvant treatment plan does not include PD(L)-1 or CTLA-4 monoclonal antibodies, patients who progress during the adjuvant treatment are allowed to participate in the study.\n8. Has signed the informed consent form, able to comply with the study protocol and follow-up plan.\n\nExclusion Criteria:\n\n1. Received treatment involving PD-1, PD-L1, or CTLA-4 antibody regimen within the past 6 months;\n2. Patients who have received treatment with thymosin, thymopentin, or thymosin a-1d within 3 months prior to enrollment.\n3. Presence of symptomatic central nervous system (CNS) metastases and\u002For carcinomatous meningitis. For subjects with previously treated CNS metastases, if the subject's condition is stable (no evidence of radiographic progression for at least weeks prior to the first administration of the study intervention, and all neurological symptoms have returned to baseline), repeat radiographic examination confirms no evidence of new brain metastases or enlargement of existing brain metastases, and no need for steroid treatment for at least 14 days prior to the first administration of the study intervention, they may participate in the study.\n4. Patients with active systemic autoimmune diseases requiring systemic treatment (i.e., using immunomodulators, corticosteroids, or immunosuppressants). Replacement therapies (such as thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) are not considered systemic treatment.\n5. Has a history of immunodeficiency, including testing positive for HIV, or suffering from other acquired or congenital immunodeficiency diseases, or has a history of organ transplantation and bone marrow transplantation.\n\n6）Allergic to the investigational drug or its components; 7）Presence of active infection requiring systemic treatment; 8) Uncontrolled internal medical complications, such as unstable congestive heart failure, unstable angina, myocardial infarction, cerebrovascular accidents, and hemodynamically unstable arrhythmias, etc.\n\n9\\) The investigator deems them unsuitable for inclusion.","60 Years",{"count":401,"type":21},55,[24],"Primary Objective:\n\nTo evaluate the effectiveness of Thymosin Alpha-1 combined with PD-1 monoclonal antibody in elderly patients with advanced melanoma .\n\nSecondary Objective:\n\nTo evaluate the safety and tolerability of adenpeptide-α1 combined with PD-1 antibody in elderly patients with advanced melanoma .\n\nStudy Design：Open-label, single-arm, non-controlled clinical trial.\n\nPrimary Inclusion Criteria:\n\n1. Age ≥60 years old;\n2. Pathologically confirmed as inoperable or metastatic melanoma;\n3. one or more lesions evaluable by RECIST1.1 standards.\n4. The Eastern Cooperative Oncology Group (ECOG) scoring system in the United States scores from 0-2;\n\nMain exclusion criteria:\n\n1. Received treatment with a regimen containing PD-1, PD-L1, or CTLA-4 antibodies within the past 6 months;\n2. Received thymosin class drug treatment within 3 months before signing the informed consent.\n3. Symptomatic, untreated central nervous system metastases. Treatment： Thymosin Alpha 1 1.6mg, sc，QD，d1-7;1.6mg, sc， three times per week, d8-21. Each 21 days is considered one cycle, for a total of 12 weeks.\n\nAnti-PD-1 monoclonal antibody (Toripalimab) 240mg per dose,ivdrip，Q3W，4 cycles.\n\nPrimary study endpoints:\n\nObjective Response Rate (ORR: CR+PR)\n\nSecondary study endpoints:\n\nProgression-Free Survival (PFS), Duration of Response (DOR), Overall Survival (OS) Adverse Events (AEs)",[405,406,407],"Melanoma","Immune-related Adverse Event","Immune Checkpoint Inhibitor","2026-06-08",{"date":261,"type":39},{"date":411,"type":39},"2023-05-30",{"date":413,"type":21},"2027-09-30",{"name":45,"class":46},2,{"id":417,"slug":4,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":228,"enrollmentInfo":422,"targetDuration":4,"studyType":22,"phases":424,"briefSummary":425,"conditions":426,"keywords":428,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":4},"100643763","NCT07636226","QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer","A Multicenter, Open-label, Randomized Controlled Phase II\u002FIII Study Evaluating the Efficacy and Safety of QL1706 in Combination With Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer","Inclusion Criteria:\n\n* 1\\. Male or female patients aged 18 years and above, up to 80 years old. 2. Small cell lung cancer or lung squamous cell carcinoma confirmed by tissue or pathological examination.\n\n  3\\. Requires previous treatment with platinum-based drugs. 4. Requires previous treatment with PD-1\u002FPD-L1 drugs. 5. Patients must have received at least 2 lines of treatment, no more than 3 lines of treatment.\n\n  6\\. Confirmed as small cell lung cancer by histological examination. 7. Able to provide informed consent and comply with the trial protocol. 8. According to RECIST 1.1 standards, there are measurable lesions (CT scan). 9. Expected lifespan ≥ 12 weeks. 10. ECOG performance status 0-1. 11. Patients must have adequate organ and bone marrow functions, defined as follows:\n  1. Absolute neutrophil count ≥ 1,500\u002FmcL\n  2. Platelet count \\> 90,000\u002FmcL\n  3. Hemoglobin ≥ 9 g\u002FdL (allowing for Hgb transfusion)\n  4. Creatinine ≤ 1.5 × ULN\n  5. Total bilirubin ≤ 1.5 mg\u002FdL or ≤ 26 μmol\u002FL\n  6. If there is liver metastasis, AST (SGOT) \u002F ALT (SGPT) ≤ 5 × ULN; if there is no liver metastasis, ≤ 2.5 × ULN\n  7. Albumin ≥ 2.5 g\u002FdL 12. Patients are allowed to receive palliative radiotherapy (such as radiotherapy after brain metastasis), provided that there are measurable target lesions in the radiation field of the patient.\n\n     13\\. Able to go to the research center to ensure that patients complete all research-related appointments.\n\n     14\\. Pregnant women and male partners of pregnant women must agree to take adequate contraceptive measures (hormonal or barrier methods; abstinence) before entering the study, during the study, and within 90 days after completing the study (hormonal or barrier methods; abstinence). If a woman becomes pregnant during the study or suspects she is pregnant, she should immediately inform the attending doctor.\n\n     Note: Pregnant women are defined as any woman meeting the following criteria (regardless of sexual orientation, whether tubal ligation has been performed or being single):\n\n  \u003C!-- -->\n\n  1. No hysterectomy or bilateral oophorectomy;\n  2. No natural menopause for at least 12 consecutive months (i.e., any time during the previous 12 months there was menstruation).\n\n     Exclusion Criteria:\n* 1\\. Patients with symptomatic central nervous system metastases, or those with unstable neurological symptoms requiring an increase in the dosage of corticosteroids.\n\n  2\\. Presence of another primary malignant tumor (excluding cervical carcinoma in situ or skin basal cell carcinoma).\n\n  3\\. The patient has a clinically significant disease that affects their participation in this study, including but not limited to: active or uncontrolled infection, SARS-CoV-2 infection, immunodeficiency, hepatitis B, hepatitis C, uncontrolled diabetes, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled arrhythmia, QTc interval prolongation \\> 450 ms or a mental illness\u002Fsocioeconomic condition that limits their compliance with the study requirements.\n\n  4\\. Previous use of CTLA-4 monotherapy or combination antibodies containing CTLA-4.\n\n  5\\. Previous treatment with anti-angiogenic drugs. 6. Presence of uncontrolled or symptomatic pleural or pericardial effusion, etc.\n\n  7\\. Uncontrolled or clinically significant third-space effusion. 8. Severe adverse reactions occurred during previous immunotherapy, and the investigator considers it unsuitable for re-administration of immunotherapy.\n\n  9\\. Any condition that may interfere with the subject's participation in the study or the evaluation of the study results.\n\n  10\\. Receiving major surgery within 30 days before the first day of the study. 11. Currently using or expected to use within 14 days before the first administration of drugs or foods known to be potent CYP3A4\u002F5 inhibitors or CYP3A4\u002F5 inducers (such as grapefruit juice or grapefruit\u002Fgrapefruit-related citrus fruits (such as oranges, grapefruits), ketoconazole, miconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, indinavir, saquanavir, ritonavir, nelfinavir, amprenavir, fosamprenavir, nefazodone, lopinavir, ritonavir), and applying these drugs locally (such as 2% ketoconazole cream is allowed);",{"count":423,"type":21},120,[24,173],"This is a multicenter, open-label, randomized controlled phase II\u002FIII study evaluating the efficacy and safety of QL1706 in combination with anlotinib as later-line treatment in patients with advanced lung cancer.",[427],"Small Cell Lung Cancer",[429,430],"small cell lung cancer","later-line","2026-06-04",{"date":388,"type":39},{"date":434,"type":21},"2026-07-30",{"date":436,"type":21},"2029-12-30",{"name":45,"class":46},{"id":439,"slug":4,"hasResults":11,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":443,"eligibilityCriteria":444,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":445,"targetDuration":4,"studyType":22,"phases":447,"briefSummary":448,"conditions":449,"keywords":451,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":457,"startDateStruct":458,"completionDateStruct":459,"leadSponsor":461,"locationsCount":69},"100643252","NCT07638436","Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma","Phase II Trial of Adebrelimab Combined With Nab-paclitaxel and Carboplatin for Neoadjuvant Therapy in Patients With Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma","NEOCRTEC2501","Inclusion Criteria:1.Voluntarily participate in the study and sign the written informed consent form.\n\n2.Aged between 18 and 75 years old. 3.Histologically confirmed thoracic esophageal squamous cell carcinoma without distant metastasis. Patients are defined as borderline resectable after enhanced computed tomography (CT), and\u002For endoscopic ultrasonography (EUS), endobronchial ultrasonography (EBUS) and multidisciplinary team (MDT) discussion.\n\n4.No prior chemotherapy or radiotherapy. 5.Estimated overall survival of no less than 3 months. 6.Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.\n\n7.Hematological parameters (tested within 7 days): Hemoglobin (Hb) ≥ 90 g\u002FL; Neutrophil count (NE) ≥ 1.5×10⁹\u002FL; Platelet count (PLT) ≥ 100×10⁹\u002FL.\n\n8.Hepatic and renal function (tested within 7 days): Total bilirubin ≤ 1.5 × upper limit of normal (ULN); Creatinine ≤ 1.5 × ULN; Aspartate transaminase (AST)\u002FAlanine transaminase (ALT) ≤ 2.5 × ULN; Alkaline phosphatase (ALP) ≤ 5.0 × ULN.\n\n9.Absence of severe complications, including active massive gastrointestinal bleeding, perforation, jaundice, intestinal obstruction, and non-neoplastic fever above 38°C.\n\n10.Fertile patients must adopt effective contraceptive measures throughout the study period.\n\n11.Good treatment compliance, and able to complete follow-up assessments for efficacy and adverse events as required by the protocol.\n\nExclusion Criteria:\n\n1. Patients with cervical esophageal squamous cell carcinoma.\n2. Patients with distant metastasis.\n3. Patients with nearly complete esophageal obstruction confirmed by endoscopy who require interventional therapy for decompression.\n4. Patients with prior placement of esophageal or tracheal stents.\n5. Patients with high risk of bleeding or perforation due to obvious tumor invasion into adjacent vital organs (major arteries or trachea), or patients with existing fistula formation.\n6. Patients with other concurrent primary malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix).\n7. Use of immunosuppressive drugs within 1 week prior to enrollment. This exclusion does not apply to intranasal, inhaled or other topical glucocorticoids, systemic glucocorticoids at physiological doses (i.e., prednisone ≤ 10 mg\u002Fday or equivalent), or glucocorticoids administered for contrast medium allergy prophylaxis.\n8. Active autoimmune diseases requiring symptomatic treatment, or a medical history of such diseases within the past 2 years.\n9. Known history of primary immunodeficiency.\n10. Confirmed active tuberculosis.\n11. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n12. Interstitial lung disease requiring corticosteroid therapy. 13Known allergy to any monoclonal antibody, chemotherapeutic agents (taxanes, carboplatin), or their excipients.\n\n14.Severe cardiac diseases, including documented congestive heart failure, uncontrolled high-risk arrhythmia, medically treated angina pectoris, clinically significant valvular heart disease, history of severe myocardial infarction, and refractory hypertension.\n\n15.Chronic diarrhea (≥4 watery stools per day) or renal insufficiency. 16.Active infection or active communicable diseases. 17.Neurological or psychiatric disorders impairing cognitive function. 18.Pregnant or breastfeeding women. 19.Other acute or chronic diseases, psychiatric disorders or abnormal laboratory findings that, in the investigator's judgment, may increase risks related to study participation or study drug administration, or interfere with the interpretation of study results.",{"count":446,"type":21},42,[24],"This clinical trial aims to preliminarily evaluate the efficacy and safety of adebrelimab combined with albumin-bound paclitaxel and carboplatin as neoadjuvant therapy for borderline resectable locally advanced esophageal squamous cell carcinoma (ESCC). The primary research objectives are to increase the R0 resection rate in such patients, thereby reducing the recurrence rate and improving overall survival (OS), as well as avoiding adverse reactions associated with radiotherapy.",[450],"Esophageal Squamous Cell Carcinoma (ESCC)",[452,453,454,455,456],"Adebrelimab","chemotherapy","neoadjuvent","immune checkpoint inhibitor","borderline resectable",{"date":325,"type":39},{"date":263,"type":21},{"date":460,"type":21},"2028-01-31",{"name":45,"class":46},{"id":463,"slug":4,"hasResults":11,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":468,"targetDuration":4,"studyType":22,"phases":470,"briefSummary":471,"conditions":472,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":476,"completionDateStruct":477,"leadSponsor":479,"locationsCount":69},"100643823","NCT07635953","New Triple Combination Therapy in Newly Diagnosed Type 2 Diabetes","Combination Therapy With Tirzepatide, Empagliflozin and Pioglitazone Versus Standard Therapy in Newly Diagnosed Type 2 Diabetes: a Multi-center Randomized Controlled Trial","Inclusion Criteria:\n\n1. Male or female, 18 years≤age≤75 years at the time of signing informed consent.\n2. Newly diagnosed with type 2 diabetes, or diagnosed within 1 years according to the WHO diagnostic criteria.\n3. Individuals who had not received previous antidiabetic therapy, or had not received antidiabetic therapy within 3 months prior to screening, or had not received antidiabetic therapy for more than 3 consecutive months or a combined total of more than 3 months in the past 2 years.\n4. 6.5%≤HbA1c≤9.0% at screening confirmed by central laboratory analysis.\n5. BMI≥24 kg\u002Fm2.\n\nExclusion Criteria:\n\n1. Individuals with type 1 diabetes or special types of diabetes.\n2. Allergy or intolerance to investigational drugs.\n3. Estimated Glomerular Filtration Rate (eGFR) \\\u003C20 mL\u002Fmin\u002F1.73 m².\n4. Individuals with heart failure in New York Heart Association \\[NYHA\\] class III or IV in the 6 months prior to randomization.\n5. History of bladder cancer or hematuria.\n6. History of Multiple Endocrine Neoplasia Type 2 (MEN 2) or relevant family history.\n7. History or family history of Medullary Thyroid Carcinoma (MTC), or susceptibility to MTC due to hereditary conditions.\n8. History of fasting blood glucose≥13.9 mmol\u002FL or the necessity for insulin use due to severe infection, diabetic foot, etc.\n9. History of acute diabetic complications: including diabetic ketoacidosis, hyperglycemic hyperosmolar state, lactic acidosis.\n10. Severe diabetic microvascular complications: proliferative retinopathy, or urinary AER\\>300mg\u002Fg, or urinary protein positive, quantitative \\>0.5g\u002F24h.\n11. Uncontrolled painful diabetic neuropathy and significant diabetic autonomic neuropathy.\n12. Severe diabetic macrovascular complications: myocardial infarction, stroke or hospitalization for unstable angina and\u002For transient ischemic attack and\u002For peripheral arterial disease required for vascular intervention or amputation within the 12 months prior to screening.\n13. Blood pressure persistently higher than 180\u002F110 mmHg and not controllable to ≤160\u002F100 mmHg within 1 week.\n14. Alanine Aminotransferase (ALT) ≥2.5 times the upper normal limit, total bilirubin ≥1.5 times the upper normal limit.\n15. Hemoglobin \\\u003C100g\u002FL or requiring regular blood transfusion.\n16. Use of medicines potentially affecting blood glucose for more than 1 week cumulatively in the past 12 weeks, such as corticosteroids, growth hormone analogs, estrogen\u002Fprogestogen, high-dose diuretics, antipsychotic drugs, etc.\n17. Participation in another trial involving medicine therapy within the past 3 months.\n18. Expected lifespan less than 2 years as per the investigator's clinical judgment, e.g., but not limited to malignancy.\n19. Pregnant or lactating females, or females of childbearing potential who cannot or are unwilling to use adequate contraception.\n20. Deemed unsuitable for participation in this clinical trial at the discretion of the investigator.",{"count":469,"type":21},296,[173],"The goal of this clinical trial is to learn the efficacy of combination therapy with tirzepatide, empagliflozin and pioglitazone versus standard therapy in newly diagnosed type 2 diabetes. The main objectives to achieve are:\n\n1. To compare efficacy of the triple combination therapy against standard therapy in achieving type 2 diabetes remission in patients newly diagnosed with T2DM.\n2. To compare the effects on β-cell function and glycemic control of the triple combination therapy against standard therapy in patients newly diagnosed with T2DM Researchers will compare drug new triple combination therapy with tirzepatide, empagliflozin, and pioglitazone to standard therapy (metformin based treatment) to see if new triple combination therapy works better in achieving type 2 diabetes remission.\n\nParticipants will:\n\n1. Take new triple combination therapy or a standard therapy every day for 6 months\n2. Visit the clinic once every 0.5-1 month for checkups and tests\n3. Keep a diary of their fingertip blood glucose and adverse events",[473],"Diabetes Mellitus","2026-06-03",{"date":388,"type":39},{"date":63,"type":21},{"date":478,"type":21},"2031-07-01",{"name":45,"class":46},{"id":481,"slug":4,"hasResults":11,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":22,"phases":488,"briefSummary":489,"conditions":490,"keywords":496,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":69},"100309067","NCT03303495","A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC","A Multinational, Randomized, Phase III Study of FOLFIRI With\u002FWithout Bevacizumab Versus Irinotecan With\u002FWithout Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer","Inclusion Criteria:\n\n1. Histologically-confirmed inoperable colorectal adenocarcinoma excluding vermiform appendix cancer and anal canal cancer.\n2. Age ≥18 years at the time of informed consent\n3. ECOG performance status (PS) of 0-2\n4. Written informed consent prior to study-specific screening procedures\n5. Life expectancy of at least 90 days\n6. Withdrawal from first-line chemotherapy (regardless of containing molecular-targeted drugs) for metastatic colorectal cancer due to intolerable toxicity or progressive disease, or relapse within 180 days after the last dose of adjuvant chemotherapy.\n7. Adequate organ function according to following laboratory values obtained within 14 days before enrolment (excluding patients who received blood transfusions or hematopoietic growth factors within 14 days before the laboratory test) Neutrophil count: ≥1500\u002Fmm3 Platelet count: ≥10.0 x 104\u002Fmm3 Hemoglobin: ≥9.0 g\u002FdL Total bilirubin: ≤1.5 mg\u002FdL AST, ALT: ≤100 IU\u002FL (≤200 IU\u002FI if liver metastases present) Serum creatinine: ≤1.5 mg\u002FdL\n\nExclusion Criteria:\n\n1. History of other malignancy with a disease-free interval \\\u003C5 years (other than curatively treated cutaneous basal cell carcinoma, curatively treated carcinoma in situ of the cervix, and gastroenterological cancer confirmed to be cured by endoscopic mucosal resection)\n2. With massive pleural effusion or ascites requiring intervention\n3. Radiological evidence of brain tumor or brain metastases\n4. Active infection including hepatitis\n5. Any of the following complication:\n\n   i) Gastrointestinal bleeding or gastrointestinal obstruction (including paralytic ileus) ii) Symptomatic heart disease (including unstable angina, myocardial infarction, and heart failure) iii) Interstitial pneumonia or pulmonary fibrosis iv) Uncontrolled diabetes mellitus v) Uncontrolled diarrhea (that interferes with daily activities despite adequate therapy)\n6. Any of the following medical history:\n\n   Myocardial infarction: History of one episode within one year before enrollment or two or more lifetime episodes i) Serious hypersensitivity to any of the study drugs ii) History of adverse reaction to fluoropyrimidines suggesting dihydropyrimidine dehydrogenase (DPD) deficiency\n7. Previous treatment with irinotecan hydrochloride\n8. Current treatment with atazanavir sulfate\n9. Previous treatment with tegafur, gimeracil, and oteracil potassium within seven days before enrollment\n10. Pregnant or lactating females, and males and females unwilling to use contraception\n11. Requires continuous treatment with systemic steroids\n12. Psychiatric disability that would preclude study compliance\n13. Otherwise determined by the investigator to be unsuitable for participation in the study\n14. Concurrent gastrointestinal perforation or history of gastrointestinal perforation with 1 year before enrollment\n15. History of pulmonary hemorrhage\u002Fhemoptysis ≥ Grade 2 (defined as bright red blood of at least 2.5mL) within 1 month prior to enrollment.\n16. History of laparotomy, thoracotomy, or intestinal resection within 28 days before enrollment\n17. Unhealed wound (except suture wounds from implantation of a central venous port), gastrointestinal ulcer, or traumatic fracture\n18. Current or recent (within 1 year) thromboembolism or cerebrovascular disease\n19. Currently receiving or requires anticoagulation therapy (\\> 325 mg\u002Fday of aspirin)\n20. Bleeding diathesis, coagulopathy, or coagulation factor abnormality (INR ≥1.5 within 14 days before enrollment)\n21. Uncontrolled hypertension\n22. Urine dipstick for proteinuria \\>+2",{"count":487,"type":21},280,[173],"The primary purpose of this study is to determine the non-inferiority of overall survival FOLFIRI with or without Bevacizumab compared with Irinotecan (CPT-11) with or without Bevacizumab as Second-line therapy in Patient with Metastatic Colorectal Cancer.",[491,492,493,494,495],"Colorectal Neoplasms","Neoplasm Metastasis","Intestinal Neoplasms","Gastrointestinal Neoplasms","Digestive System Neoplasms",[497,498,499,500],"FOLFIRI","CPT-11","Bevacizumab","2nd-line metastatic colorectal cancer",{"date":502,"type":39},"2026-06-05",{"date":504,"type":39},"2011-11-14",{"date":506,"type":21},"2026-12-31",{"name":45,"class":46},{"id":509,"slug":4,"hasResults":11,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":4,"eligibilityCriteria":513,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":514,"targetDuration":4,"studyType":22,"phases":516,"briefSummary":517,"conditions":518,"keywords":520,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":522,"startDateStruct":523,"completionDateStruct":524,"leadSponsor":526,"locationsCount":69},"100640059","NCT07630077","Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities","Evaluation of the Efficacy and Safety of Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Gene Abnormalities in a Phase II Clinical Trial","Inclusion Criteria:\n\n\\- 1. The subjects voluntarily participated in this study and signed the informed consent form, showing good compliance; 2. Age: 18 - 75 years old (at the time of signing the informed consent form); 3. ECOG PS score: 0 - 1 point; 4. Expected survival period: more than 3 months; 5. According to the International Association for the Study of Lung Cancer and the 8th edition of the American Joint Committee on Cancer's Lung Cancer TNM staging system, patients with locally advanced (stage IIIB\u002FIII C), metastatic or recurrent (stage IV) NSCLC that cannot be treated surgically and cannot receive radical concurrent radiotherapy and chemotherapy, and whose cancer is confirmed by cytology or histology, are eligible for this study. (Note: Mixed tumors will be classified according to the main cell type; if there is a small cell component, the subject does not meet the inclusion criteria); 6. Cohort 1: Previous first-line treatment failed, and HER2 amplification or overexpression (2+ or 3+) is required; Cohort 2: Patients who received no systematic treatment at the initial diagnosis, with HER2 amplification or overexpression (2+ or 3+), and with PD-L1 ≥ 1%; 7. At least one measurable lesion must be present according to the RECIST 1.1 standard. Lesions that have received radiotherapy cannot be regarded as target lesions unless there is a clear progression after radiotherapy; 8. Patients must have adequate organ and bone marrow functions, defined as follows:\n\n1. Absolute neutrophil count ≥ 1,500\u002FmcL\n2. Platelet count \\> 90,000\u002FmcL 19\n3. Hemoglobin ≥ 9 g\u002FdL (allow for blood transfusion)\n4. Creatinine ≤ 1.5 × ULN\n5. Total bilirubin ≤ 1.5 mg\u002FdL or ≤ 26 μmol\u002FL\n6. If there is liver metastasis, AST (SGOT) \u002F ALT (SGPT) ≤ 5 × ULN; if there is no liver metastasis, ≤ 2.5 × ULN\n7. Albumin ≥ 2.5 g\u002FdL 9. Both the reproductive-aged women and their male partners must agree to take adequate contraceptive measures (hormonal or barrier methods; abstinence) before entering the study, during the study, and within 90 days after completing the study (hormonal or barrier methods; abstinence). If a woman becomes pregnant during the study or suspects she is pregnant, she should immediately inform the attending physician.\n\nNote: Reproductive-aged women are any women who meet the following criteria (regardless of sexual orientation, whether they have undergone tubal ligation or chosen to remain single):\n\n1. No hysterectomy or bilateral oophorectomy;\n2. No natural menopause for at least 12 consecutive months (i.e., any time during the previous 12 months there was menstruation).\n\nExclusion Criteria:\n\n* 1\\. Have previously received treatment with anti-HER2 drugs, including large molecule antibodies, TKIs, ADCs, etc.; 2. Have a history of interstitial lung disease, radiation pneumonitis, or immune-related pneumonitis after using steroids, or have active non-infectious pneumonia with interstitial lung changes during the screening period, active pulmonary tuberculosis, pneumoconiosis, or having ≥2 grade other types of pneumonia, or severe impairment of lung function (FEV1 or DLCO or DLCO\u002FVA as a percentage of the predicted value is less than 40%) confirmed by lung function tests, etc.; 3. Have experienced arterial\u002Fdeep vein thrombosis events within 6 months before treatment, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism, etc.; 4. Have ≥2 grade myocardial ischemia or myocardial infarction, arrhythmias (including QTcF ≥ 450ms (male), QTcF ≥ 470ms (female), and ≥2 grade congestive heart failure (New York Heart Association (NYHA) classification), left ventricular ejection fraction (LVEF) \\\u003C 50%; angina pectoris requiring anti-myocardial ischemia drugs; clinically significant heart valve disease); 5. Have active autoimmune diseases or autoimmune disease history, including but not limited to Crohn's disease, ulcerative colitis, autoimmune hepatitis\u002Fenteritis\u002Fvasculitis\u002Frenalitis, etc., except for the following situations: ① Controllable type I diabetes; ② Hypothyroidism controlled by hormone replacement therapy; ③ Skin diseases that do not require systemic treatment (such as vitiligo, psoriasis); ④ Other diseases that are expected not to recur (such as asthma that has been cured in childhood); 6. Need systemic or local use of immunosuppressants to achieve the purpose of immunosuppression and still need to continue using them within 2 weeks before randomization; 7. Have pleural effusion (thoracic cavity, abdominal cavity or pericardial cavity) with repeated drainage to relieve clinical symptoms (judged by the investigator), or have received pleural effusion drainage for therapeutic purposes within 2 weeks before treatment; 8. Have symptomatic or progressive CNS metastasis or cancerous meningitis, with diffuse dissemination; Have a history of brain metastasis and if the subject is clinically stable, can be considered for inclusion.",{"count":515,"type":21},30,[24],"This is a phase II trial in patients with locally advanced or metastatic non-small cell lung cancer harboring HER2 gene abnormalities （amplification or overexpression）with a performance status of 0 to1 who are planned to receive first-line treatment or who have falied the first-line treatment",[519],"Non Small Cell Lung Cancer",[521],"HER2 gene abnormalities (amplification or overexpression)",{"date":502,"type":39},{"date":63,"type":21},{"date":525,"type":21},"2028-07-01",{"name":45,"class":46},{"id":528,"slug":4,"hasResults":11,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":22,"phases":535,"briefSummary":536,"conditions":537,"keywords":539,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":547,"leadSponsor":549,"locationsCount":69},"100640989","NCT07621497","FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)","A Prospective, Multicenter, Randomized Controlled, Phase II Study to Evaluate the Efficacy and Safety of FOLFOX8 Versus mFOLFOX6 Combined With Bevacizumab or Cetuximab as First-Line Treatment for Unresectable Metastatic Colorectal Cancer","Inclusion Criteria:\n\n1. Age ≥ 18 years, male or female.\n2. ECOG performance status 0-2.\n3. Histologically or cytologically confirmed unresectable metastatic colorectal cancer with no prior treatment for unresectable or metastatic disease.\n4. Adequate organ function: Hb ≥ 70 g\u002FL; WBC ≥ 3.0×10⁹\u002FL; NEUT ≥ 1.5×10⁹\u002FL; PLT ≥ 75×10⁹\u002FL; AST and ALT ≤ 3× ULN; sCr ≤ 2× ULN; TBIL ≤ 2× ULN.\n5. Expected survival \\> 3 months.\n\nExclusion Criteria:\n\n1. Known allergy to the study drug(s) and\u002For their excipients.\n2. Contraindications to chemotherapy.\n3. Patients with MSI-H or dMMR colorectal cancer.\n4. Patients with BRAF mutation.\n5. Pregnant or breastfeeding women.\n6. History of any second malignancy within 2 years prior to randomization, except for cured localized tumors such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, cervical carcinoma in situ, or breast carcinoma in situ, which are allowed for enrollment.\n7. Patients with systemic medical or psychiatric disorders that make them unsuitable for chemotherapy.\n8. Patients deemed unsuitable for enrollment in this study by the investigator's judgment.\n9. Participation in another clinical trial of an investigational drug within 4 weeks prior to randomization.",{"count":534,"type":21},229,[24],"This is a prospective, multicenter, randomized controlled, phase II study. It is expected to enroll 229 patients and aims to evaluate the efficacy and safety of FOLFOX8 versus mFOLFOX6 combined with bevacizumab or cetuximab as first-line treatment for unresectable metastatic colorectal cancer. The primary objective is to assess progression-free survival (PFS) of the patients. Secondary objectives include assessment of objective response rate (ORR), overall survival (OS), safety, and other outcomes.",[538],"Metastatic Colorectal Cancer (CRC)",[540,541,542],"FOLFOX8","Levofolinic Acid For Injection","First-line treatment","2026-05-31",{"date":545,"type":39},"2026-06-02",{"date":65,"type":21},{"date":548,"type":21},"2030-06-01",{"name":45,"class":46},{"id":551,"slug":4,"hasResults":11,"nctId":552,"briefTitle":553,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":555,"targetDuration":4,"studyType":22,"phases":556,"briefSummary":557,"conditions":558,"keywords":560,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":564,"completionDateStruct":565,"leadSponsor":567,"locationsCount":69},"100639861","NCT07622771","Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR\u002FMSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial","Inclusion Criteria:\n\n1. Patients or their family members agree to participate in the study and sign the informed consent form;\n2. Age 18-75 years, male or female;\n3. Locally advanced rectal adenocarcinoma confirmed by histopathology;\n4. Clinical stage cT3-4bN0M0 or cTxN+M0, with or without MRF positive, with or without EMVI positive, expected to R0 resection;\n5. without intestinal obstruction;\n6. ECOG PS 0-1;\n7. expect survival up to 2 years;\n8. White blood cell count \\> 3.5×109\u002FL；Platelet count ≥ 100×109\u002FL；Hemoglobin ≥ 80 g\u002FL；\n9. ALT ≤ 1.5×ULN, AST ≤ 1.5×ULN ；\n10. Serum creatinine ≤ 100μmol\u002Fl,\n\nExclusion Criteria:\n\n1. With inguinal lymph node metastasis or lateral lymph node metastasis (lymph node diameter ≥7 mm, or lymph node morphology and MRI features consistent with typical metastatic lymph nodes);\n2. Arrhythmia requiring antiarrhythmic treatment (except beta-blockers or digoxin), symptomatic coronary artery disease or myocardial ischemia (myocardial infarction within the last 6 months), or congestive heart failure exceeding NYHA Class II;\n3. Severe hypertension poorly controlled with medication;\n4. History of HIV infection, or active hepatitis B (HBV DNA ≥ 2000 IU\u002FmL or 10⁴ copies\u002FmL), or hepatitis C (positive hepatitis C antibody with HCV-RNA above the lower limit of detection of the assay);\n5. Active pulmonary tuberculosis (TB), currently receiving anti-tuberculosis treatment, or having received anti-tuberculosis treatment within 1 year prior to screening;\n6. Other active clinically severe infections (NCI-CTCAE Version 5.0);\n7. Preoperative evidence of distant metastasis outside the pelvis;\n8. Cachexia or organ function decompensation.\n9. History of pelvic or abdominal radiotherapy;\n10. Multiple primary colorectal cancers;\n11. Patients with seizures requiring treatment (e.g., corticosteroids or antiepileptic therapy);\n12. History of other malignancies within 5 years, except cured cervical carcinoma in situ or basal cell carcinoma of the skin;\n13. Drug abuse, or medical, psychological, or social conditions that may interfere with the patient's participation in the study or affect the evaluation of study results;\n14. Active autoimmune disease or history of autoimmune disease (including but not limited to: interstitial pneumonia, uveitis, enterocolitis, hepatitis, hypophysitis, nephritis, hyperthyroidism, and hypothyroidism);\n15. Receipt of any anti-infective vaccine (e.g., influenza vaccine, varicella vaccine, etc.) within 4 weeks prior to enrollment;\n16. Comorbidities requiring long-term treatment with immunosuppressive agents, or requiring systemic or local administration of corticosteroids at immunosuppressive doses (dose \\>10 mg\u002Fday of prednisone or other glucocorticoids with equivalent efficacy);\n17. Known or suspected hypersensitivity to the investigational drug, or to any medication administered in relation to this study;\n18. Any unstable condition that may jeopardize patient safety or compliance;\n19. Pregnant or lactating women, or women of childbearing potential not using adequate contraception;\n20. Refusal to sign the informed consent form.",{"count":115,"type":21},[24],"To explore the efficacy and safety of radiotherapy combined with Adebrelimab and NALIRIFOX in patients with pMMR\u002FMSS locally advanced rectal cancer",[559],"Rectal Cancers",[211,561,150,324],"immunotherapy","2026-05-28",{"date":474,"type":39},{"date":65,"type":21},{"date":566,"type":21},"2032-12-31",{"name":45,"class":46},{"id":569,"slug":4,"hasResults":11,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":4,"eligibilityCriteria":573,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":574,"targetDuration":4,"studyType":22,"phases":576,"briefSummary":577,"conditions":578,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":580,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":69},"100640327","NCT07622784","Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma","A Single-Arm, Open-Label, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Pirtobrutinib as Maintenance Therapy for Relapsed or Refractory B-Cell Lymphoma After CAR-T Cell Therapy","Inclusion Criteria:\n\n* Able to understand and voluntarily sign the informed consent form.\n* Age 18 years or older, male or female.\n* Histologically confirmed large B-cell lymphoma, including diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, or transformed follicular lymphoma (tFL).\n* Eastern Cooperative Oncology Group performance status of 0 to 2.\n* Has received commercial anti-CD19 CAR-T cell therapy, with informed consent obtained before Day 28 after CAR-T cell infusion.\n* Prior anti-lymphoma therapy-related adverse events, especially CAR-T-related adverse events, have stabilized and recovered to Grade 1 or lower, except for clinically insignificant toxicities.\n\nExclusion Criteria:\n\n* History of other malignancies, except non-melanoma skin cancer without recurrence for more than 3 years, carcinoma in situ, such as cervical, bladder, or breast carcinoma, or follicular lymphoma.\n* Prior autologous or allogeneic hematopoietic stem cell transplantation.\n* Active or suspected uncontrolled fungal, bacterial, viral, or other infection requiring intravenous treatment. Patients with uncomplicated urinary tract infection or uncomplicated bacterial pharyngitis may be enrolled if responding to active treatment.\n* History of immunodeficiency, including human immunodeficiency virus infection; positive treponema pallidum antibody; active hepatitis B virus infection; or active hepatitis C virus infection.\n* Current or prior history of benign central nervous system disease, such as seizure, cerebrovascular ischemia or hemorrhage, dementia, cerebellar disease, or any central nervous system-related autoimmune disease.\n* Lymphoma involvement of the atrium or ventricle.\n* Autoimmune disease requiring systemic immunosuppressive or immunomodulatory therapy within 2 years.\n* History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months before enrollment.\n* Any comorbidity that may affect or interfere with safety or efficacy assessment.",{"count":575,"type":21},20,[24],"This is a single-arm, open-label, multicenter clinical study to evaluate the efficacy and safety of pirtobrutinib as maintenance therapy in patients with relapsed or refractory B-cell lymphoma after commercial anti-CD19 CAR-T cell therapy.",[579],"Relapsed or Refractory B-cell Lymphoma",{"date":474,"type":39},{"date":582,"type":21},"2026-06",{"date":584,"type":21},"2028-12",{"name":45,"class":46},{"id":587,"slug":4,"hasResults":11,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":592,"targetDuration":4,"studyType":22,"phases":594,"briefSummary":595,"conditions":596,"keywords":599,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":607,"leadSponsor":609,"locationsCount":69},"100640296","NCT07615283","Adebrelimab Combined With SHR2554 in Relapsed\u002FRefractory PTCL and NK\u002FT-Cell Lymphoma","A Single-Arm, Multicenter, Phase Ib\u002FII Exploratory Study to Evaluate Adebrelimab in Combination With EZH2 Inhibitor SHR2554 for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma and NK\u002FT-Cell Lymphoma","Inclusion Criteria:\n\n1. Age ≥18 years old,regardless of gender;\n2. Centrally confirmed histopathological\u002Fcytologic diagnosis of PTCL with the following subtypes:\n\n   1. Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS);\n   2. Systemic anaplastic large cell lymphoma (ALK+ and ALK-);\n   3. Follicular helper T (TFH) cell lymphoma of lymph nodes, including angioimmunoblastic, follicular, NOS;\n   4. NKTCL\n   5. and any other PTCL subtypes deemed by the investigator to be eligible for inclusion.\n3. Met the criteria of relapsed\u002Frefractory lymphoma: Relapsed lymphoma was defined as relapsed lymphoma after achieving complete response (CR) or partial response(PR)after initial therapy. Refractory is defined as having an evaluation of progressive disease (PD) after 2 cycles, or stable disease (SD) after 4 cycles of a previous systemic therapy regimen.\n4. There must be at least one measurable or evaluable lesion that meets the Lugano 2014 criteria for lymphoma: Measurable lesion: Nodal lesions with major diameter greater than 1.5cm and minor diameter greater than 1.0cm as assessed by PET\u002FCT or Computed Tomography (CT) and\u002For Magnetic Resonance Imaging (MRI); Or the length of extranodal lesions \\>1.0cm; 2)Evaluable lesions: PET-CT showed increased uptake in lymph nodes or extranodal regions (higher than liver) and imaging features consistent with lymphoma;\n5. ECOG performance status score: 0-2;\n6. Expected survival time ≥3 months;\n7. Have adequate organ and bone marrow function, defined as follows(The patients had not received granulocyte growth factor, platelet transfusion, or red blood cell transfusion within 14 days before the examination):\n\n   1. Blood routine: absolute neutrophil count (ANC) ≥ 1.0×109\u002FL;\n   2. platelet count (PLT) ≥ 60×109\u002FL;\n   3. hemoglobin (HGB) ≥ 8.0 g\u002FdL;\n   4. white blood cell (WBC) ≥ 3.5×109\u002FL;\n   5. Renal function: serum creatinine (Cr) ≤1.5×ULN.or creatinine clearance (CrCl) ≥ 40 mL\u002Fmin (calculated using the Cockcroft-Gault formula);\n   6. serum total bilirubin (TBIL) ≤1.5× upper limit of normal value ;\n   7. alanine aminotransferase (ALT) and aspartate transferase (AST) ≤2.5×ULN ;\n   8. Coagulation function: International Normalized Ratio (INR) ≤1.5 × ULN; Prothrombin Time (PT), Activated PartialThromboplastin Time (APTT) ≤1.5×ULN (unless the subject is receiving anticoagulant therapy, And PT and APTT at screening were within the expected range for anticoagulant therapy).\n   9. Thyroid stimulating hormone (TSH) or free thyroxine (FT4) or free triiodothyronine (FT3) within the normal range ±10% (Note: non-autoimmune causes of abnormal TSH, FT3 and FT4 can be maintained in the normal range after replacement treatment of hypothyroidism can be enrolled).\n8. Capable of understanding the study procedures and voluntarily signing a written informed consent form (ICF).;\n9. Women of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose of medication; Effective contraception should be used from the time of informed consent until 6 months after the last dose of study drug.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. Patients with hemophagocytic lymphohistiocytosis;\n3. Primary central nervous system (CNS) lymphoma or secondary CNS involvement.\n4. History of allogeneic organ transplantation;\n5. Received allogeneic hematopoietic stem cell transplantation (allo-HSCT) within 3 years prior to the first dose of study drug (patients who received allo-HSCT \\> 3 years prior to the first dose of study drug and currently have no active graft-versus-host disease \\[GVHD\\] are eligible to enroll);\n6. Known allergy or hypersensitivity to the study drugs or their related metabolites;\n7. Uncontrolled active infection;\n8. Currently participating in another clinical study, or less than 4 weeks elapsed from the end of treatment in a previous clinical study to the planned start of study treatment;\n9. Planned autologous hematopoietic stem cell transplantation (auto-HSCT);\n10. Less than 3 months elapsed since the last dose of prior treatment with any immune checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4).\n11. Active autoimmune disease that required systemic treatment within the past 2 years (hormone replacement therapy is not considered systemic treatment, e.g., type 1 diabetes mellitus, hypothyroidism requiring only thyroxine replacement therapy, or adrenal\u002Fpituitary insufficiency requiring only physiologic doses of corticosteroids). Patients with an autoimmune disease that did not require systemic treatment within the past 2 years are eligible to enroll;\n12. Required systemic treatment with corticosteroids or other immunosuppressive agents for any condition within 14 days prior to the start of study treatment (except for topical or short-term use of corticosteroids, or corticosteroids used for non-autoimmune conditions such as delayed-type hypersensitivity caused by contact allergens);\n13. Diagnosis of another malignancy within the past 5 years, except for malignancies treated with curative intent, including basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the breast, or carcinoma in situ of the cervix.\n14. Received systemic anti-tumor therapy within 28 days prior to the start of study treatment, including chemotherapy, immunotherapy, and biological therapy (tumor vaccines, cytokines, or growth factors to control cancer);\n15. Underwent major surgery within 28 days, or received radiotherapy within 90 days prior to the start of study treatment;\n16. Received live vaccines within 28 days prior to the start of study treatment (excluding attenuated influenza vaccines);\n17. Patients with a known history of Human Immunodeficiency Virus (HIV) infection and\u002For acquired immunodeficiency syndrome;\n18. Patients with active chronic hepatitis B or active hepatitis C. Hepatitis B SurfaceAntigen (HBsAg) or hepatitis B core Antibody (HBcAb) or Hepatitis C Virus (HCV) during the screening period HCV) antibody positive patients must be further tested for Hepatitis B Virus (HBV) DNA (no more than 2500 copies \u002FmL or 500 IU\u002FmL) and HCV RNA (no more than the lower limit of detection of the assay), Enrollment in the trial occurred after the exclusion of patients with active hepatitis B or hepatitis C infection requiring treatment. Hepatitis B virus (HBV) carriers, medically stable hepatitis B (DNA \\> 2500 copies \u002FmL or 500IU\u002FmL) and cured hepatitis C patients are eligible for enrollment.\n19. Active tuberculosis (TB);\n20. Uncontrolled fungal or bacterial infections;\n21. Known history of alcohol or substance abuse;\n22. Uncontrolled comorbidities, including but not limited to symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, active peptic ulcer, or bleeding disorders;\n23. History of interstitial lung disease or non-infectious pneumonitis (subjects with a history of asymptomatic drug-induced or radiation-induced non-infectious pneumonitis are eligible for enrollment);\n24. QTcF interval \\> 450 msec, unless secondary to bundle branch block;\n25. History of psychiatric disorders;\n26. Severe concomitant diseases that, in the judgment of the investigator, would compromise patient safety or interfere with the patient's ability to complete the study;\n27. Any other condition that, in the opinion of the investigator, makes the patient unsuitable for inclusion in this study.",{"count":593,"type":21},40,[279,24],"To evaluate the safety of adebrelimab combined with SHR2554 in the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) and NK\u002FT-cell lymphoma (NKTCL), to determine the recommended Phase 2 dose (RP2D) of the combination regimen, and to assess preliminary efficacy.",[597,598],"Relapsed or Refractory Peripheral T Cell Lymphoma","NKTCL",[600,601,602],"SHR2554","adebrelimab","EZH2 inhibitor","2026-05-22",{"date":605,"type":39},"2026-05-29",{"date":605,"type":21},{"date":608,"type":21},"2030-10-29",{"name":45,"class":46},""]